Device and method for controlling in-vivo pressure

Abstract
A differential pressure regulating device is provided for controlling in-vivo pressure in a body, particular in a heart. The device may include a shunt being positioned between two or more lumens in a body, to enable fluids to flow between the lumens, and an adjustable flow regulation mechanism being configured to selectively cover an opening of the shunt to regulate the flow of fluid through the shunt in relation to a pressure difference between the body lumens. In some embodiments, a control mechanism coupled to the adjustable flow regulation mechanism may be provided to remotely activate the adjustable flow regulation mechanism.
Description
FIELD OF THE INVENTION

The present invention relates to devices and methods for reducing or regulating pressure within a circulatory system, and in particular, to regulate blood pressure in a heart.


BACKGROUND OF THE INVENTION

CHF is recognized as one of the most common causes of hospitalization and mortality in Western society, and has a great impact on the quality of life. CHF is a disorder characterized by low systemic perfusion and inefficient cardiac function. CHF causes may include myocardial insult due to ischemia, cardiomyopathy, and other processes. Pathophysiologic mechanisms that are directly associated with CHF include reduced cardiac output, increase in cardiac filling pressures, and fluid accumulation, which may lead to, for example, pulmonar congestion and dyspnea. Impairment of systolic function may result in poor left ventricular contraction and reduced cardiac output, which may generate clinical symptoms including effort intolerance, dyspnea, reduced longevity, edema (lung or peripheral), and pain. A patient with systolic dysfunction may usually have a larger left ventricle because of phenomena called cardiac remodeling aimed to maintain adequate stroke-volume. This pathophysiologic mechanism is associated with increased atrial pressure and left ventricular filling pressure. With abnormal diastolic function, the left ventricle may be stiff and markedly less compliant, partly because of abnormal relaxation leading to inadequate cardiac filling at normal pressures. Maintenance of adequate cardiac filling at higher filling pressures may be needed to maintain cardiac output. This mandatory rise of filling pressure to maintain cardiac filling and output may lead to pulmonary venous hypertension and lung edema.


Presently available treatments for CHF fell into three general categories: (1) pharmacological, e.g., diuretics; (2) assist systems, e.g., pumps; and (3) surgical treatments. With respect to pharmacological treatments, vasodilators have been used to reduce the workload of the heart by reducing systemic vascular resistance and diuretics to prevent fluid accumulation and edema formation, and reduce cardiac filling pressure.


Assist devices used to treat CHF may include, for example, mechanical pumps. Mechanical pumps reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Currently, mechanical pumps are used, for example, to sustain the patient while a donor heart for transplantation becomes available for the patient. There are also a number of pacing devices used to treat CHF. Resynchronization pacemakers have also been used to treat CHF. Finally, there are at least three extremely invasive and complex surgical procedures for treatment of heart failure: 1) heart transplant; 2) dynamic cardiomyoplasty, and 3) the Batista partial left ventriculostomy.


In extreme acute situations, temporary assist devices and intraaortic balloons may be helpful. Cardiac transplantation and chronic left ventricular assist device (LVAD) implants may often be used as a last resort. However, all the assist devices currently used are intended to improve pumping capacity of the heart and increase cardiac output to levels compatible with normal life, reducing filling pressures and/or preventing edema formation. Finally, cardiac transplantation may be used to treat extreme cardiac dysfunction cases, however, (the original has no comma here but it should be) this procedure is highly invasive and is limited by the availability of donor hearts. The mechanical devices may allow propulsion of significant amount of blood (liters/min), and this is also their main limitation. The need for power supply, relatively large pumps, and possibility of hemolysis and infection are all of concern.





BRIEF DESCRIPTION OF THE DRAWINGS

The subject matter regarded as the invention is particularly pointed out and distinctly claimed in the concluding portion of the specification. The invention, however, both as to organization and method of operation, together with features and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanied drawings in which:



FIG. 1A is a schematic illustration of a Differential Pressure Regulation Device (DPRD), in accordance with an exemplary embodiment of the invention;



FIGS. 1B-1I are schematic illustrations of additional embodiments of Differential Pressure Regulation Devices (DPRD), in accordance with some embodiments of the invention;



FIG. 1J is a chart describing an example of a pressure curve related to the relationship between the change in pressure difference between two lumens, the flow through the flow control mechanism and the orifice area, in accordance with an exemplary embodiment of the present invention;



FIGS. 2A and 2B are schematic illustrations of a cross-section view and a side view, respectively, of an adjustable shunt, tube, or other structure in accordance with an exemplary embodiment of the invention;



FIG. 3 is a schematic illustration of a shunt in accordance with another exemplary embodiment of the invention;



FIG. 4 is a schematic illustration of a shunt including a Flow Regulation Mechanism (FRM) in accordance with an exemplary embodiment of the invention;



FIG. 5 is a schematic illustration of the shunt of FIG. 4 and incorporating a FRM in an open state in accordance with an exemplary embodiment of the invention;



FIG. 6 is a schematic illustration of a FRM in accordance with another exemplary embodiment of the invention, which may be used, for example, in conjunction with the DPRD of FIG. 1, the shunt of FIGS. 2A-2B, or the shunt of FIG. 3;



FIG. 7 is a schematic illustration of a FRM in accordance with another exemplary embodiment of the invention, which may be used, for example, in conjunction with the DPRD of FIG. 1, the shunt of FIGS. 2A-2B, or the shunt of FIG. 3;



FIG. 8 is a schematic illustration of a FRM in accordance with another exemplary embodiment of the invention, which may be used, for example, in conjunction with the DPRD of FIG. 1, the shunt of FIGS. 2A-2B, or the shunt of FIG. 3;



FIG. 9 is a schematic illustration of a FRM within a heart, in accordance with another exemplary embodiment of the invention;



FIG. 10 is a schematic illustration of a FRM in accordance with another exemplar embodiment of the invention, which may be used, for example, in conjunction with the DPRD of FIG. 1, the shunt of FIGS. 2A-2B, or the shunt of FIG. 3;



FIG. 11 is a schematic illustration of a FRM in accordance with another exemplary embodiment of the invention, which may be used, for example, in conjunction with the DPRD of FIG. 1, the shunt of FIGS. 2A-2B, or the shunt of FIG. 3;



FIG. 12 is a schematic illustration of a FRM in accordance with another exemplary embodiment of the invention, which may be used, for example, in conjunction with the DPRD of FIG. 1, the shunt of FIGS. 2A-2B, or the shunt of FIG. 3;



FIG. 13A is a schematic illustration of an apparatus for remotely controlling a DPRD in accordance with some embodiments of the present invention;



FIGS. 13B-E are schematic illustrations of mechanisms for remotely controlling a DPRD, in accordance with some embodiments of the present invention; and



FIG. 14 is a flow chart illustrating a method of controlling pressure, for example, blood pressure in a heart, according to some embodiments of the present invention.





It will be appreciated that for simplicity and clarity of illustration, elements shown in the figures have not necessarily been drawn to scale. For example, the dimensions of some of the elements may be exaggerated relative to other elements for clarity. Further, where considered appropriate, reference numerals may be repeated among the figures to indicate corresponding or analogous elements.


SUMMARY

The present invention may provide methods and devices for regulating pressure in a body. According to some embodiments of the present invention, a differential pressure regulating device may include a shunt being positioned between two or more lumens in a body, to enable fluids to flow between the lumens, and an adjustable flow regulation mechanism being configured to selectively cover an opening of the shunt, to regulate the flow of fluid through the shunt in relation to a pressure difference between the body lumens.


According to some embodiments, (they added a comma here even though the master does not have a comma, I agree with it) the pressure regulating device may include a shunt being positioned between two or more chambers in a heart, to enable fluids to flow between the chambers, an adjustable flow regulation mechanism being configured to selectively cover the opening of the shunt, to regulate the flow of fluid through the shunt, and a control mechanism to be coupled to the adjustable flow regulation mechanism, to remotely activate the adjustable flow regulation mechanism.


In another embodiment, a method is provided to control in-vivo pressure, which may include implanting a differential pressure regulation device in a body, the pressure regulation device including a shunt placed between two or more lumens in a body, deploying a flow regulation mechanism, and controlling the flow regulation mechanism setting according to changes in pressure differences between the lumens.


In a further embodiment of the present invention, (same here) a method is provided to control in-vivo pressure, which may include controlling a flow regulation mechanism flow setting using a control mechanism implanted in a body, the flow regulation mechanism being disposed within a differential pressure regulation device that includes a shunt placed between two or more lumens, for example, between a left atrium of a heart and a right atrium of a heart.


DETAILED DESCRIPTION OF EMBODIMENTS OF THE PRESENT INVENTION

In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those of ordinary skill in the art that the present invention may be practiced without these specific details. In other instances, well-known methods, procedures, components, and structures may not have been described in detail so as not to obscure the present invention.


It will be appreciated that although part of the discussion herein may relate, for exemplary purposes, to a heart, heart chambers and/or heart atriums, embodiments of the present invention are not limited in this regard, and may be used in conjunction with various other vessels, lumens, organs or body sites. For example, some embodiments of the present invention may include regulating fluid transfer between cavities in the brain, between selected organs, between blood vessels (e.g., between the aorta and the vena-cava), etc., and/or between other suitable lumens, for example, zones, cavities, organs, vessels, regions or areas in a body.


Some embodiments of the present invention include, for example, a method and apparatus for controlling in-vivo pressure by reducing or otherwise controlling pressure differences between two or more body sites, for example, two chambers of the human heart (e.g., the left atrium and the right atrium). For example, such pressure control may be used to help solve the problem of increased cardiac filling pressure in patients with congestive heart failure and predominantly diastolic dysfunction, thereby helping to minimize or prevent pulmonary fluid accumulation, edema formation, and clinical complaint of dyspnea. In another example, the pressure control may be used to reduce left ventricle filling pressure. Some embodiments of the invention may include a Differential Pressure Regulation Device (DPRD), for example, including a shunt, tube, or other structure having an orifice, tube, or opening to fluidically connect two or more lumens, for example, to connect a left atrium of a heart with a right atrium of the heart. In accordance with some embodiments of the invention, the DPRD may include an adjustment mechanism or a regulation mechanism, able to adjust, modify or otherwise regulate, for example, the cross-sectional area of the orifice, for example, in relation to a change in pressure difference between the first and second lumens, for example, such as to increase and/or decrease the flowrate of blood between the two lumens.


Some embodiments of the present invention may be used, for example, to unload an excessive filling pressure of a left heart ventricle in a Congestive Heart Failure (CHF) patient, and to potentially prevent or reduce the occurrence of pulmonary edema.


Some embodiments of the present invention include, for example, implanting an adjustable DPRD in a wall between two heart chambers, e.g., between the left atrium and the right atrium. The pressure regulation device may, for example, allow a selective volume of blood to flow from the left atrium to the right atrium, in relation to the change in pressure difference between the left atrium and the right atrium. The pressure regulation device may, for example, be adjusted to selectively change the size or shape of the opening, amount of blood allowed to flow through, etc.


In some embodiments, the pressure regulation device may be configured to maintain a continual flow between two or more lumens, for example, between the left atrium and the right atrium. For example, a shunt, tube, or other structure may be coupled to a cover, valve opening, valve stem, or other flow regulation mechanism that may be configured to be continually ajar, to enable a selected minimal quantity of fluid to continually flow between two lumens in a body, for example, between the heart chambers. The cover may be subsequently adjusted, for example, may be farther opened and/or closed, to control the quantity of fluid flow between the lumens. The fluid flow through the DPRD may increase or decrease in accordance with changes in the pressure or pressure difference between the two lumens. For example, cover may be opened and/or closed as the pressure in the left atrium increases or decreases relative to the pressure in the right atrium. In some embodiments, the DPRD may be configured such that the orifice cover has no direct contact with the shunt opening to reduce help minimize or prevent tissue growth on or around the orifice cover. Such a configuration may enable a continuous fluid flow through the DPRD, and may help to prevent or reduce the occurrence of clotting or formation of biofilm or other unwanted growths. In some embodiments, the DPRD may be used to flush or clean out the shunt and/or shunt cover etc.


Reference is made to FIG. 1A, which schematically illustrates a DPRD 101 implanted in a heart 109, in accordance with an exemplary embodiment of the present invention. DPRD 101 may be implanted between two or more body lumens, for example, between a left atrium 102 and a right atrium 103 of heart 102. DPRD 101 may be implanted in other heart chambers, using different arrangements of heart chambers, and/or in or between other body lumens. In some embodiments, an opening, puncture or other structure may be formed in a wall between two body lumens, for example, in septum 105 between left atrium 102 and right atrium 103, for example, using a puncturing or cutting device mounted to the distal end of a catheter or any other suitable puncturing mechanism. DPRD 101 may then be placed in a puncture using a catheter or another suitable delivery mechanism. In some embodiments, one or more tissue fixation elements, for example, support arms 106, may support DPRD 101 at a desired position in a generated hole or puncture.


DPRD 101 may include, for example, an adjustable shunt, tube, or pathway 122 to enable fluids to flow between two body lumens, organs, regions or zones, etc., for example, between a left atrium 102 and a right atrium 103. DPRD 101 may include a Plow Regulation Mechanism (FRM) 108 as described herein, for example, a flow valve, cover, valve opening, valve stem, or lid, to enable selected modification of the parameters of shunt 122, for example, by changing the cross-section of the opening of shunt 122 or the shunt's shape, etc., thereby regulating the blood flow from left atrium 102 to right atrium 103. In some embodiments, FRM 108 may be set in a continually ajar position to enable a continual flow of blood between the left atrium and the right atrium. For example, FRM 108 may be purposefully left ajar, to enable a selected quantity of blood to continually flow between the heart chambers. FRM 108 may be subsequently adjusted, for example, by selectively changing the size or shape of the opening, amount of blood allowed to flow through, etc., to enable the area around the opening of shunt 122 and FRM 108 to be limited and/or expanded, thereby affecting effective flow-through of shunt 122, and enabling the quantity of blood flow between the chambers to be controlled. DPRD 101 may include one or more control mechanisms 110, for example, wires, springs, cords, etc., to enable FRM 108 to be passively and/or actively controlled. In one embodiment, springs may be used to enable FRM 108 to act in accordance with changes in differential pressure, for example, by being pre-loaded with a selected tension, to respond in a controlled way to changes in one or more pressure thresholds.


FRM 108 may be configured to respond to selective pressure profiles, thereby providing a known pressure relief profile. For example, FRM 108 may be pre-set, pre-calibrated and/or pre-configured to change its setting, adjust its configuration or position, and/or change the orifice width or flow amount, etc., in accordance with changes in pressure difference between the left and right atriums of the heart. FRM 108 may be continually adjustable, for example, to a continuously variable setting, for example, in response to environmental conditions and/or external controls. In at least these ways, DPRD 101 may provide a selected, predictable and/or guaranteed flow of fluid between two or more bodily lumens or regions, etc. In some embodiments, the resting or default setting, opening size, flow level, or position of FRM 108 may be changed, for example, according to pre-programmed parameters and/or remote control mechanisms. In some embodiments, a continuously open or ajar FRM 108 may help prevent occlusion of shunt 122.


In some embodiments, below a certain pressure or pressure differential, the valve or device may be folly closed; however, in other embodiments, below a certain pressure or pressure differential, the valve may be not fully closed or slightly ajar. For example, the valve may have a minimum opening size.


In some embodiments, one or more properties of the DPRD, for example, the size of the cross-section opening of the pressure regulation device, may be dependent on the blood pressure difference between the left atrium and the right atrium. Therefore, in some embodiments, the blood flow between the left atrium and the right atrium may be influenced by the change in blood pressure difference between the left atrium and the right atrium.


A DPRD, according to some embodiments of the invention, may allow for a reduction in ventricular pressure by reducing pressure in an atrium of the heart.


In some embodiments, a DPRD may be used for Atrium Septum Defect (ASD) patients, for example, who may not be able to tolerate a complete uncontrolled atrium closure procedure, to selectively close a hole or gap in the septum.


In some embodiments, a DPRD may be used to transfer fluid from the left atrium to the right atrium, for example, to aid a patient with pulmonary hypertension. In such cases, the DPRD may be positioned with FRM 108 in the left atrium. According to some embodiments of the present invention, FRM 108 may be unidirectional or bi-directional.


In some embodiments, a plurality of DPRD's may be implanted in a wall or other structure, for example, to help provide redundancy, to implant devices with different set ranges to achieve a higher level of opening control, and/or to enable adding of additional devices. Implanting a plurality of DPRD's may enable the delivering catheter diameter to be reduced, two or more DPRD's of a lesser diameter may be delivered.


In other embodiments, FRM 108 may include a cover, lid, or other suitable mechanisms that may have various forms to enable partial or total closure of FRM 108. Reference is now made to FIGS. 1B-1G. In FIG. 1B FRM 108 may include two or more arms 120, which may be configured to be continuously or constantly ajar at opening 125 of shunt 122. For example, FRM 108 may be configured to remain continually at least partially detached from shunt 122, to allow a continuous flow of fluid between left atrium 102 and right atrium 103. Arms 120 may be further opened and/or closed in response to changes in pressure differences between the heart chambers, Arms 120 may be constructed from a flexible polymer or other suitable materials. Arms 120 may have rounded shapes at arm ends 130, for example, to help prevent blood stagnation.


In FIG. 1C, FRM 108 may include a shunt 122, and two or more flexible membranes 135, which may be configured to be constantly ajar at opening 125 to enable a continuous blood flow through shunt 122. For example, in the various embodiments discussed herein, a device may be set so that no matter what the pressure or pressure differential between chambers, a minimum opening size may be set, or flow amount may occur. Membrane 135 may include at least one spring-type mechanism, to help expand and/or contract membrane 135, in response to changes in pressure differences between the heart chambers.


In FIG. 1D FRM 108 may include a shunt 122, and one or more flexible or spring-based lid, membrane, or leaflets 150, optionally connected to shunt 122 by a spring or other suitable pressure-sensitive mechanism 155. In one embodiment pressure-sensitive mechanism 155 may be pre-loaded to respond in a controlled way to changes in one or more pressure thresholds. Lid 150 may be configured to be constantly ajar at opening 125 to enable a continuous blood flow through shunt 122. FRM 108 may include one or more raised areas 160, for example, thorn-shaped objects or objects with other suitable shapes to help prevent lid 150 from making fall contact with shunt 122.


In FIG. 1E FRM 108 may include a shunt 122, and one or more angled flexible membranes or leaflets 165, which may be configured to be constantly ajar at opening 125 to enable a continuous blood flow through shunt 122. In one embodiment, leaflets 165 may be pre-loaded with a selected tension to respond in a controlled way to changes in one or more pressure thresholds. Leaflet 165 may include at least one spring mechanism or other suitable mechanisms to help close and/or open leaflet 165 in response to changes in pressure differences between the heart chambers. Leaflet 165 may include at least one magnet or electromagnet 170 or other suitable mechanisms to help remotely close and/or open leaflet 165. A conducting wire 172 or other suitable mechanisms may be used to activate magnet(s) or electromagnet(s) 170.


In FIG. 1F, FRM 108 may include a shunt 122, and a cap, valve opening, valve stem, or other mechanism 175, which may be configured to be constantly ajar at opening 125 to enable a continuous blood flow through shunt 122. Cap 175 may be coupled to a spring 177 or other suitable pressure-sensitive mechanism. In one embodiment, spring 177 may be pre-loaded with a selected tension to respond in a controlled way to changes in one or more pressure thresholds may include one or more cap motion limiters 179. FRM 108 may include a fixed polarized magnet 181 and an electromagnetic coil 183 that includes one or more conductors 185. Cap 175 may be opened and/or closed in response to changes in pressure differences between the heart chambers and/or by remotely activating magnet 181 and/or magnetic coil 183. For example, when magnet 181 is activated cap 175 may be further opened, and when coil 183 is activated cap 175 may be further closed.


As shown in FIG. 1G, FRM 108 may include a shunt 122, and a cap 175, which may be configured to be constantly ajar at opening 125 to enable a continuous blood flow through tube 122. Cap 175 may be connected to shunt 122 by a connection arm 185. Cap 175 may include cuts, slots, grooves or slits, etc. 187 to enable a continuous blood flow through shunt 122. Slots 187 may be of different sizes, depths, widths, or densities, which may help dictate whether various areas of cap 175 are to be stronger and less flexible or weaker and more flexible, and may therefore respond differently to changes in pressure differences between the bodily lumens. For example, in an area where there are more or deeper incursions, the area may be relatively weak and flexible, thereby allowing cap 175 to be at least partially opened by a relatively low pressure blood flow through shunt 122. In an area where there are fewer and/or more superficial incursions, the area may be relatively strong or less flexible, thereby only allowing cap 175 to be at least partially opened by a relatively high pressure blood flow through shunt 122.


As shown in FIGS. 1H and 1I, FRM 108 may include a shunt 122, and a cap 175, which may be configured to be constantly ajar at opening 125 to enable a continuous blood flow through shunt 122. Cap 175 may be coupled to a spring 190 or other suitable pressure-sensitive mechanism. Spring 190 and cap 175 may be connected to a piston or pump mechanism 192. As can be seen in FIG. 1I, cap 175 may be opened and/or closed in response to changes in pressure differences between the heart chambers and/or by piston 192 activating spring 190 to extend and/or distend cap 175, thereby changing the size of opening(s) 125.


According to some embodiments of the present invention, the usage of DPRD 101 may enable generation of a pressure curve related to the relationship between the change in pressure difference between two lumens, the flow through the flow control mechanism, and the orifice area. Any required or selected design parameters may be used. Reference is now made to FIG. 1J, which illustrates an example of such a pressure curve. As can be seen in FIG. 1J, below a pressure differential of 12 mmHg, the opening or orifice size may be relatively stable, and flow may be influenced substantially by the pressure difference. When pressure difference rises above approximately 12 mmHg until approximately 20 mmHg, the flow may increase at a higher rate, as it may now be influenced by both the increase in orifice area and the increase in pressure difference. When pressure difference rises above approximately 20 mmHg, the flow rate increase at a slower rate, since the orifice area may have already reached its maximum cross-section, and the flow may be influenced substantially by the pressure difference. Pressure differences and/or may be affected by linear and/or non-linear changes in the orifice area. Other pressure difference, flow and/or orifice area levels, relationships, and interrelationships may be used, as may other parameters, variables, minimum and maximum limits, etc.


Reference is made to FIGS. 2A and 2B, which schematically illustrate a cross-section view and a side view, respectively, of an adjustable DPRD 201 in accordance with an exemplary embodiment of the invention. DPRD 201 may include, for example, a frame 220 connected to one or more support arms, e.g., arms 211-216. Frame 220 may include, for example, a flexible fixation frame, ring, or tube. Frame 220 may be formed from a flexible material, for example, a flexible metal, superelastic alloy, and/or a shape-memory material, e.g., Nitinol or other suitable materials.


Although DPRD 201 is described herein as having six arms or appendages 211-216, for exemplary purposes, embodiments of the present invention are not limited in this regard and may include a different number of arms, for example, one arm, two arms, ten arms, or the like.


Arms or appendages 211-216 may be flexible and/or may be pre-shaped to achieve a desired functionality. For example, arms 211-216 may be folded during an insertion process, e.g., inside a suitable delivery tube. In some embodiments, arms 211-216 may be formed of a superelastic material, for example, a Shape-Memory Alloy (SMA), e.g., nickel-titanium (NiTi) alloy. Other suitable materials may include, for example, metals, stainless steel, and/or other suitable materials. At least part of arms 211-216 or other selected elements of DPRD 201 may be coated and/or textured to increase their bio-compatibility and/or to increase the degree to which these elements may become selectively endothelialized, as may be desired in some implantation conditions.


DPRD 201 may include, for example, an FRM 250, for example, including a cover, valve opening, valve stem, or other flow regulation mechanism with one or more pre-set positions, to selectively cover an orifice resulting from the deployment of DPRD 201. FRM is described in detail below.


As illustrated schematically in FIG. 2B, DPRD 201 may have two sides, which may be referred to herein as a proximal side 251 and a distal side 252, respectively. For example, DPRD 201 may be implanted in heart 109, such that the proximal side 251 of DPRD 201 may face the right atrium 103, and the distal side 252 of DPRD 201 may face the left atrium 102. Other orientations of sides 251 and 252 may be used, as may other numbers of sides.


In some embodiments, the distal side 252 of DPRD 201 may be connected to a distal set of arms or appendages, e.g., arms 211-213, and the proximal side 251 of DPRD 201 may be connected to a proximal set of arms or appendages, e.g., arms 214-216. Thus, when DPRD 201 is implanted in heart 109, the distal set of arms 211-213 may first be discharged in the left atrium 102, e.g., to the right of septum 105 in FIG. 1, thus supporting DPRD 201 to the left side, from the patient's perspective, of septum 105. Then, as the insertion of DPRD 201 is completed, e.g., by retracting a catheter or delivery tube carrying DPRD 201, the proximal set of arms 214-216 may be discharged in the right atrium 103, e.g., to the left of septum 105 in FIG. 1, thus supporting the right side, from the patient's perspective, of septum 105. In this manner, arms 211-216 may support frame 220 of DPRD 201 at a desired position between the left atrium 102 and the right atrium 103.


Reference is now made to FIG. 3, which schematically illustrates a DPRD 301 in accordance with another exemplary embodiment of the present invention. DPRD 301 may include, for example, a frame 302 connected to one or more arms or appendages, for example, arms 303 and 304.


Frame 302 may include, for example, a flexible fixation frame formed from a flexible material, for example, a flexible metal, e.g., Nitinol or Nitinol wire. Frame 302 may have a generally helical shape, for example, as schematically illustrated in FIG. 3, and may be integrally formed with curved arms 303 and 304 at either end of frame 302, as schematically illustrated in FIG. 3. Other suitable shapes may be used. Arms 303 and 304 may be flexible and may be pre-shaped to achieve a desired functionality. For example, arms 303 and 304 may be folded during an insertion process, e.g., inside a suitable deliver tube, in order to be subsequently discharged for positioning the frame 302 in a puncture. In accordance with some exemplary embodiments of the present invention, DPRD 301 may include an FRM 350, for example, an FRM as detailed herein.


Reference is also made to FIG. 4, which schematically illustrates a DPRD 401 including a DPRD 450 in accordance with an exemplary embodiment of the invention. DPRD 450 may be an example of FRM 250 or FRM 350. For exemplary purposes only, DPRD 450 is shown in conjunction with a DPRD 401 which may be similar to DPRD 201, although DPRD 450 may be used in conjunction with DPRD 301 or any other suitable shunts or medical devices.


DPRD 450 may include, for example, a disk 432 connected to a ring 431 by a spring 433. Disk 432 may be formed of a bio-compatible material, for example, pyrolytic carbon or stainless steel. Spring 433 may include one or more swivel springs, twisting springs, or any other spring elements, which may hold disk 432 inside ring 431 when there is substantially no pressure differential between the two sides of DPRD 401, e.g., between the proximal side 251 and the distal side 252 of DPRD 201 of FIG. 2B.


In response to a pressure differential between the two sides of DPRD 401, disk 432 may move away from the atrium having the relatively higher pressure, typically the left atrium, bending spring 433, which may apply a counterforce to the movement of disk 432, thereby opening and/or enlarging a cavity through which blood may pass. The counterforce applied by spring 433 may depend on the pressure differential between the two sides of DPRD 401, for example, when the pressure in an atrium forces spring 433 to contract, such that the higher the pressure differential across DPRD 401, the larger the opening to allow relief of such pressure differential by flow from the high-pressure side to the low-pressure side. In this manner, the pressure differential between the proximal and distal sides of DPRD 401 may be controlled in accordance with one or more selected levels. In some embodiments, the various configurations for DPRDs described herein may allow for opening sizes or flow rates that vary continuously with pressure differentials.


It will be appreciated that when there is substantially no pressure difference between the two sides of DPRD 401, or when the pressure difference is relatively small, disk 432 may be fully closed, or in addition may not entirely block the flow of blood through DPRD 450, for example, through the area between disk 432 and ring 431. For example, disk 432 may be selectively set with a gap between ring 431 and disk 432, such that disk 432 may function as a leaking valve to enable blood to continuously flow through a puncture. The continual freedom of flow across DPO 401 may, for example, prevent blood clotting and/or thrombus formation in and/or around disk 432.


In some embodiments, ring 432 may be asymmetric, for example, ring 432 may have a relatively wider upper section 451 and a relatively narrower lower section 452. This may allow, for example, blood passage at a relatively small flowrate during tilting of disk 432 under increased pressure, until disk 432 bends beyond the upper section of ring 431, thereby providing a pressure or pressure differential threshold at which the valve opens or begins to open, to increase the blood flow cross-section through the vessel. The pressure threshold may be a continual (e.g., infinitely variable) set of pressure points at which the valve opens or allows a pressure flow in accordance with the pressure. For example, the valve may remain closed or slightly ajar until a certain pressure, then above that pressure open continually until an upper pressure is reached, at which the valve is fully open. It is noted that an asymmetric ring 432 or other asymmetric components may be used to achieve similar functionality in various other FRMs, DPRDs, shunts and/or devices in accordance with embodiments of the present invention.


In some embodiments, ring 431 may be formed of, for example, a suitable metal. In some embodiments, ring 431 may be integrated within frame 220, or ring 431 and frame 220 may be implemented using an integrated ring-frame component. Ring 431 and/or frame 220 may be formed of a suitable wire or tube. Ring 431 and/or arms 211-216 may be formed of a suitable wire or tube, e.g., the same wire or tube and/or the same material.


Reference is also made to FIG. 5, which schematically illustrates DPRD 401 implanted in heart 109, incorporating DPRD 450 in an open state in accordance with an exemplary embodiment of the present invention. A pressure difference may exist between left atrium 102 and right atrium 103, for example, the pressure in left atrium 102 may be larger than the pressure in right atrium 103. The pressure difference may cause disk 432 to move towards right atrium 103 and bend the spring 433, thereby creating an enlarged opening through which more blood may flow from left atrium 102 to right atrium 103. As the blood flows towards right atrium 103, the pressure in left atrium 102 may decrease, and the pressure in the right atrium may increase, thereby reducing the pressure difference between the left atrium 102 and the right atrium 103, and allowing spring 433 to pull back disk 432 towards a closed or substantially closed position. Other mechanisms to enable disk 432 to move may be used.



FIG. 6 schematically illustrates a DPRD 650 in accordance with another exemplary embodiment of the invention. DPRD 650 may be an example of FRM 108, FRM 250, or FRM 350. DPRD 650 may include, for example, ring 431 and a pre-shaped wire 634. Wire 634 may include a flexible metal wire, for example, formed of Nitinol or other suitable materials. In one embodiment, wire 634 may be curved to a shape of a horse-shoe or tongue or another suitable shape. In some embodiments, an end of wire 634 may be attached to ring 431, or wire 634 and ring 431 may be formed of the same wire, tube, or other suitable material.


Wire 634 may be covered by or connected to a cover or sheet 635, which may include, for example, a flat sheet of bio-compatible material, for example, a biological tissue material used in conjunction with artificial valve leaflets. Sheet 635 may be attached to wire 634, for example, using one or more stitches 636.


DPRD 650 may be included in, for example, DPRD 201 or DPRD 301, implanted in heart 109. A pressure difference may exist between left atrium 102 and right atrium 103. For example, the pressure in left atrium 102 may be larger than the pressure in right atrium 103. The pressure difference may cause sheet 635 to move, utilizing the elasticity of wire 634, thereby creating a cavity through which blood may flow from left atrium 102 to right atrium 103. As the blood flows in that direction, the pressure in left atrium 102 may decrease, and the pressure in the right atrium may increase, thereby reducing the pressure difference between the left atrium 102 and the right atrium 103, and allowing sheet 635 to move back towards a closed or substantially closed position or towards a position wherein sheet 635 is in a marginally opened position.


It is noted that when there is no pressure difference between the left atrium 102 and the right atrium 103, or when the pressure difference is relatively small, sheet 635 may not entirely block a blood flow through DPRD 650, for example, through the area around sheet 635, or between sheet 635 and ring 431. This may, for example, prevent blood clotting and/or thrombus formation in and/or around sheet 635 or DPRD 650. However, as with the other configurations discussed herein, in other embodiments, the opening or valve may be completely closed at certain pressure differentials.



FIG. 7 schematically illustrates a PRM 750 in accordance with another exemplary embodiment of the invention. FRM 750 may include, for example, ring 431 connected to a cone 737 using one or more springs 738. Cone 737 may be positioned inside ring 431, and may be formed of, for example, a bio-compatible material, e.g., pyrolytic carbon or stainless steel. Cone 737 may have a suitable shape, for example, rectangular, square-shaped, circular, oval, trapezoid-shaped, cone-shaped, or other suitable shapes,


FRM 750 may be included in a shunt, e.g., DPRD 201 or DPRD 301, implanted in heart 109. Springs 738 may include one or more compression springs, and may hold cone 737 inside ring 431, for example, when substantially no pressure difference exists between left atrium 102 and right atrium 103.


When a pressure difference exists between left atrium 102 and right atrium 103, for example, when the pressure in left atrium 102 is larger than the pressure in right atrium 103, FRM 750 may allow blood flow from left atrium 102 to right atrium 103. The pressure difference may cause cone 737 to move back against springs 738, thereby opening or enlarging a cavity through which blood may flow from left atrium 102 to right atrium 103. As the blood flows in that direction, the pressure in left atrium 102 may decrease, and the pressure in the right atrium may increase, thereby reducing the pressure difference between the left atrium 102 and the right atrium 103, and allowing cone 737 to move back towards a closed or substantially closed position.


It is noted that when there is no pressure difference between the left atrium 102 and the right atrium 103, or when the pressure difference is relatively small, cone 737 may not entirely block a blood flow through FRM 750, for example, through the area around cone 737, or between cone 737 and ring 431. This may, for example, prevent blood clotting and/or thrombus formation in and/or around cone 737 or FRM 750.



FIG. 8 schematically illustrates an FRM 850 in accordance with another exemplary embodiment of the invention. FRM 850 may include, for example, a flexible valve 839 connected to and positioned inside ring 431. Valve 839 may be formed of, for example, a bio-compatible material, e.g., polyurethane or silicone. Valve 839 may be attached to ring 431, for example, by gluing or stitching a base 840 of valve 839 inside ring 431. Valve 839 may include one or more leaflets, for example, leaflets 841 and 842 are able to move and create or enlarge an opening 843. In some embodiments, the size of opening 843 may be in relation to a pressure applied to leaflets 841 and 842.


FRM 850 may be included in a shunt, tube, or conduit, e.g., DPRD 201 or DPRD 301, implanted in heart 109. When a pressure difference exists between left atrium 102 and right atrium 103, for example, when the pressure in left atrium 102 is larger than the pressure in right atrium 103, FRM 850 may allow blood flow from left atrium 102 to right atrium 103. The pressure difference may stretch, spread or push leaflets 841 and/or 842, thereby increasing the distance between them and enlarging the opening 843, through which blood may flow from left atrium 102 to right atrium 103. As the blood flows in that direction, the pressure in left atrium 102 may decrease, and the pressure in the right atrium may increase, thereby reducing the pressure difference between the left atrium 102 and the right atrium 103, and allowing leaflets 841 and/or 843 to move back towards a closed or substantially closed position.


It is noted that when there is no pressure difference between the left atrium 102 and the right atrium 103, or when the pressure difference is relatively small, valve 839 and leaflets 841 and 842 may not entirely block blood flow through 850, for example, through the opening 843. This may, for example, prevent blood clotting and/or thrombus formation in and/or around valve 839 or FRM 850.



FIG. 9 schematically illustrates a DPRD 950 within heart 109, in accordance with another exemplary embodiment of the invention. DPRD 950 may include a plurality of balloons or sacs inter-connected through one or more tubes, for example, a non-compliant balloon 943 connected through a tube 944 to a compliant balloon 945. The non-compliant balloon 943 may be placed in the left atrium 102 and/or in a puncture, and the compliant balloon 945 may be placed in the right atrium 103. In some embodiments, balloons 943 and/or 945 may be attached to a ring (e.g., ring 431). In some embodiments, balloons 943 and/or 945 may contain a liquid 920.


Liquid 920 may flow from balloon 943 to balloon 945 or vice versa, for example, in relation to a pressure difference between the left atrium 102 and the right atrium 103. For example, when there is a relatively larger pressure in the left atrium 102, liquid 920 may flow from non-compliant balloon 943 through tube 944 to compliant balloon 945, thereby deflating the non-compliant balloon 943 and inflating the compliant balloon 945. It is noted that compliant balloon 945 may be more flexible than non-compliant balloon 943, allowing the compliant balloon 945 to act as a spring mechanism to control the deflating of the non-compliant balloon 943.



FIG. 10 schematically illustrates a DPRD 1050 in accordance with another exemplary embodiment of the invention. DPRD 1050 may include, for example, ring 431 and a flexible disk 1046 having a hole 1047. In some embodiments, hole 1047 may be substantially circular and may be located, for example, substantially in the center of flexible disk 1046. Flexible disk 1046 may be formed of, for example, a flexible polymeric material, e.g., silicone rubber or polyurethane.


DPRD 1050 may be implanted in heart 109, and hole 1047 may change its diameter in relation to a pressure difference between the left atrium 102 and the right atrium 103. For example, the pressure difference may push backward or stretch the flexible disk 1046, thereby enlarging the hole 1047 and allowing a larger area through which blood may flow from the left atrium 102 to the right atrium 103.


It is noted that when there is no pressure difference between the left atrium 102 and the right atrium 103, or when the pressure difference is relatively small, hole 1047 may still be open and may have a relatively small diameter, and flexible disk 1046 may not entirely block a blood flow through DPRD 1050. This may, for example, prevent blood clotting and/or thrombus formation in and/or around DPRD 1050.



FIG. 11 schematically illustrates a DPRD U50 in accordance with another exemplary embodiment of the invention. DPRD 1150 may include, for example, a balloon or sac 1148, such as a non-compliant balloon containing a liquid 1120. The balloon 1148 may be placed or connected inside a ring 1131, which may include, for example, a ring similar to ring 431 and/or a frame. A tube 1149 may connect balloon 1148 to a reservoir 1155, which may include one or more pistons 1151 able to move against one or more compression springs 1152. Springs 1152 may be formed of, for example, metal or a suitable elastic material.


DPRD 1150 may be implanted in heart 109, and balloon 1148 may change its volume in relation to a pressure difference between the left atrium 102 and the right atrium 103. For example, the pressure difference may push or deflate the balloon 1148, thereby causing liquid 1120 to flow from balloon 1148 to reservoir 1155. This may create or enlarge an opening inside ring 1131, through which blood may flow from the left atrium 102 to the right atrium 103.



FIG. 12 schematically illustrates a DPRD 1250 in accordance with another exemplary embodiment of the invention. DPRD 1250 may include, for example, a balloon 1148, such as a non-compliant balloon containing a liquid 1120. The balloon 1148 may be placed or connected inside a ring 1131, which may include, for example, a ring similar to ring 431 and/or a frame. A tube 1149 may connect balloon 1148 to a reservoir 1155, which may include one or more pistons 1151 able to move. The piston 1151 may be moved, for example, using a motor 1153, which may include an electric motor, e.g., a step motor or other suitable motors. Motor 1153 may move, push or pull pistons 1151, thereby causing liquid 1120 to flow from balloon 1148 to reservoir 1155 or vice versa. This may change the volume of balloon 1148, thereby increasing or decreasing a size of an opening inside ring 1131, through which blood may flow from the left atrium 102 to the right atrium 103.


According to some embodiments of the present invention, the DPRD may be actively controlled, for example, by a patient or medical service provider. In one embodiment, DPRD may be operated using external and/or manually provided instructions. For example, motor 1153 may operate in accordance with external and/or manually provided instructions. Additionally or alternatively, motor 1153 may operate in relation to a pressure difference between the left atrium 102 and the right atrium 103. For example, a pressure-dependent close loop 1260 may be used, incorporating one or more pressure transducers 1254. The pressure transducers 1254 may measure an absolute pressure in one or more heart chambers, for example, in left atrium 102 and/or right atrium 103, or may measure a differential pressure between two heart chambers, for example, between left atrium 102 and right atrium 103. Based upon the pressure information, motor 1153 may operate and move, push or pull the pistons 1151.


In other embodiments, DPRD may be remotely operated using one or more of electric mechanisms, mechanical mechanisms, wireless mechanisms, pneumatic mechanisms, or other suitable mechanisms. For example, a wire, line, spring, pin, cable, hook, latch, motor, or magnet may be connected to the DPRD to enable the DPRD to be remotely controlled by a patient and/or medical service provider. As can be seen with reference to FIG. 13A at least one line or control lead 1320 may connect DPRD 1300 to a control mechanism 1310, for example, a control box. For example, control lead 1320 may exit vein 1330 through a puncture or hole 1335. Control mechanism 1310 may include, for example, a mechanical interface, electrical interface, pull/push wire, spring, magnet, or other suitable elements or mechanisms to enable DPRD 1300 to be remotely controlled.


Control mechanism 1310 may be a micro mechanism that may be placed internally or externally, for example, it may be sown into tissue under a patient's skin, to provide external access for a medical service provider, or it may be placed internally in proximity to a location that may be accessed by a medical service provider with a minimally invasive technique.


In one embodiment, DPRD 1300 may be controlled wirelessly from an external ‘transmitting’ unit. For example, control signals may be delivered from outside a patient's body using telemetry localized RF radiation, localized Ultrasound radiation, external magnetic field, localized heating, and other suitable means of generating signals. In such an embodiment, DPRD 1300 may include a ‘receiving’ unit. The receiving unit may include an internal power source (e.g., a battery), or may receive its energizing power from the control signal or other transmitted signals. The receiving unit may be coupled to an external power source, for example, via an implanted plug, or may be directly connected to DPRD 1300 on a temporary basis (e.g., at the doctor's office), where the implanted plug may relay command signals and/or power to activate DPRD 1300.


Reference is now made to FIG. 13B, which indicates an example of a control mechanism 1310 being positioned under the skin surface 1360. In one example, control lead 1320 may be accessed by entering the patient using a conventional needle or syringe 1365, for example, by making a small incision. Control lead(s) 1320 may be controlled externally or internally to enable DPRD 1300 to be controlled. In some embodiments, control lead(s) 1320 may operate within a tube, for example, a silicon pressurized tube 1370. Control mechanism 1310 may include a remote valve opening/closing mechanism, for example, to enable monitoring of heart pressure, monitoring of DPRD functioning, etc. In one example, control mechanism 1310 may be used to monitor blood flow changes in response to valve positioning. Control mechanism 1310 may enable manual reduction of heart pressure or in blood pressure in certain chambers of the heart in the case of clinical need. Control mechanism 1310 may enable flushing or clewing of DPRD 1300 at selected intervals, for example, by increasing internal blood pressure or fluid pressure. In other embodiments, flushing or cleaning may be enabled using a flushing or cleaning fluid, for example, saline solution that may be entered into control lead 1320 at a selected pressure to cause the orifice to be cleaned or flushed. Such cleaning may help in reducing undesired growth, infections, etc., associated with DPRD 1300.


Control mechanism 1310 may be coated with one or more substances to prevent thrombosis or other conditions, DPRD 1300 may include spikes, thorns, or other suitable mechanisms to prevent an FRM from being in foil contact with a shunt, or to ensure only minimal contact between an FRM and a shunt. Control mechanism 1310 may enable parts of DPRD 1300 to be remotely replaced, cleaned, serviced, or otherwise manipulated. Control mechanism 1310 may enable a pre-configured or designed leak to be remotely opened, closed, or otherwise changed in accordance with clinical requirements. Control mechanism 1310 may enable blocking up of the DPRD's orifice or cavity, for example, by remotely placing a plug in the orifice to cease functioning of the DPRD. One or more of the above qualities may enable a health service provider to remotely control the functioning of DPRD 1300.


In one embodiment, as can be seen with reference to FIG. 13C, control mechanism 1310 may include one or more push knobs 1340 or other suitable controls or mechanisms that may be controlled using a finger or other suitable implement. For example, the various push knobs 1340 may be pushed individually, simultaneously and/or in various other combinations to achieve a desired effect in DPRD 1300. In one embodiment, control mechanism 1310 may include, for example, one or more rods or electric conductors 1350 to help control DPRD 1300. In one embodiment, control mechanism 1310 may include, for example, one or more security mechanisms 1345, for example, a locking button to help prevent non-required changes from being made to the operation of DPW 1300. In other embodiments, control mechanism 1310 may include one or more springs or other suitable control mechanisms coupled to rod 1350 and DPRD 1300.


In one embodiment, as can be seen with reference to FIG. 13D, control mechanism 1310 may be used to control DPRD 1300, for example, using one or more rods or wires 1375, etc., optionally operating within tube 1370. DPRD 1300 may include a cover 1377, for example, flexible or non-flexible cover, which may be left constantly ajar, for example, to form gap 1379. In one embodiment, cover 1377 may be constructed from a rigid material and may be assembled or connected in a rigid manner to a locking mechanism 1380. Once cover 1377 has been set in a selected position by locking mechanism 1380, it may remain stable, for example, not being affected by blood pressure changes, until cover 1377 is re-positioned. In such a case, cover 1377 may only be adjusted by intentional and controlled actions using control mechanism 1310, for example, wires 1375 using signals, or other suitable communication links.


Locking mechanism 1380 may enable cover 1377 to be remotely set in one or more positions. Locking mechanism 1380 may include, for example, one or more of a spring, latch, lever, notch, slot, hook, slide, or other suitable locking mechanism(s). For example, position #1 may be a lower position, for example, where the hook 1325 fastens onto the catching mechanism 1332 as indicated; position #2 may be a medium position, for example, where the hook 1325 fastens onto the catching mechanism 1333; position #3 may be a higher position for example where the hook 1325 fastens onto the catching mechanism 1334. Other settings, opening sizes, levels, positions and numbers of positions may be used. Control mechanism 1310 may include security features, for example, to help prevent unauthorized personnel from activating DPRD 1300 (e.g., special tools and magnets, coded sequence, password, etc.).


In one embodiment, as can be seen with reference to FIG. 13E, control mechanism 1310 may be used to control DPRD 1300, for example, using an auxiliary hydraulic system. DPRD 1300 may be connected to the hydraulic system, for example, via one or more tubes 1390 that may help control the pressures and/or flow rates of fluids delivered through DPRD 1390. DPRD 1390 may be connected to the hydraulic system when required, or may be permanently attached to the hydraulic system. In one embodiment, tubing 1390 may increase the fluid pressure in DPRD 1300, for example, to provide significant force on or inside the shunt. Tubing 1390 may additionally or alternatively be used for “maintenance,” for example, by forcing liquid through the shunt, for example, via shunt base 1392, to flush, clean and/or lubricate the shunt and/or FRM 1396, and/or to release moving parts in DPRD 1300 in order to keep DPRD 1300 in a required operating condition or state. In one example, a substance (e.g., saline solution) may be injected and/or extracted to/from tubing 1390 to change the pressure at base 1392 and thereby activate piston diaphragm 1394. Piston diaphragm 1394 may be extended and/or distended, thereby causing FRM 1396 to be manipulated, for example, to open and/or close FRM 1396, to allow fluid to selectively flow through DPRD 1300. Tube 1390 may be connectable to tube 1320 (see FIGS. 13A and 13B) and/or to a needle 1366, or other suitable device for penetrating a patient's skin to connect to tube 1390. In one embodiment, the hydraulic mechanism may be used after deployment of DPRD 1300 in the body, for example, to verify operability of DPRD 1300. In a further embodiment, the hydraulic mechanism may be used when checking DPRG operability following deployment of DPRD 1300 in the body.


It will be appreciated that some embodiments of the present invention may use one or more threshold values, pre-defined parameters, conditions and/or criteria, for example, to trigger an activation or a de-activation of a shunt, a DPRD, or an FRM.


Various suitable techniques for implanting a device according to an embodiment of the invention may be used. According to some embodiments, the pressure regulation device may be delivered and implanted in a patient's body using a minimally invasive procedure, for example, using percutaneous delivery. In such an example, the device may be mounted on a catheter delivery system and inserted into the body via a small incision. Once the device is in the correct location inside the body, it may be deployed by an operator, expanded, and locked in place. A device that is delivered on a catheter may be, for example, contracted or folded into a small dimension, and the device may self-expand upon deployment. In other embodiments, the pressure regulation may be delivered using invasive surgery, for example, where a surgeon makes a larger opening in the body in order to achieve more direct contact with the device implantation location.


In one embodiment of the present invention, as described in embodiments in U.S. patent application Ser. No. 09/839,643, entitled “METHOD AND APPARATUS FOR REDUCING LOCALIZED CIRCULATORY SYSTEM PRESSURE” and filed on Apr. 20, 2001, in particular in FIGS. 3-5, a transseptal needle set may be advanced toward the wall of the right atrial septum. Access may be made from the femoral vein, with the apparatus being advanced through the inferior vena cava and into the right atrium. Once transseptal puncture has been achieved, a guidewire may be exchanged for a needle component and then passed into the left atrium. The process of securing catheter access to the left atrium by way of a transseptal puncture is known in the art. After a transseptal sheath is positioned in the left atrium, as described above, the placement of a shunt made in accordance with embodiments of the present invention may be initiated.


The dilator and wire may subsequently be withdrawn from the sheath that may now extend from the femoral vein access point in the patient's groin to the left atrium, traversing the femoral vein, the iliac vein, the inferior vena cava, the right atrium, and the atrial septum, etc. The delivery catheter may be passed through the sheath while under fluoroscopic visualization. Radiopaque markers may be provided on this catheter as well as the sheath in order to locate specific points. The delivery catheter may be carefully and slowly advanced so that the most distal portion of the left-atrial fixation element is emitted from the distal opening of the catheter and into the chamber of the left atrium. The fixation elements may be formed from a spring-like material and/or may be a super-elastic of shape-memory alloy, so that as it leaves the constraint provided by the inner area of the delivery catheter, it reforms into its pre-configured fully formed shape. The assembly of the sheath and the delivery catheter may then slowly be retracted en bloc so as to withdraw the fixation elements towards the atrial septum. The physician may stop this retraction when it becomes apparent by fluoroscopic visualization as well as by tactile feedback that the fixation element has become seated against the atrial septum. At that point, the sheath alone may be retracted, uncovering the shunt and positioning it within the opening that has been created within the atrial septum. The sheath may then be further retracted, allowing the right-atrial fixation element to reform into its folly-formed shape. The entire shunt assembly or DPRD may then be detached from the delivery catheter system. The DPRD may be controlled within the delivery catheter by means of long controller wire that has independent translational control within the catheter area. This attachment may be formed by any conventional method, e.g., a solder or adhesive or the like that may mechanically detach at a prescribed tension level, that level being exceeded by the physician at this point in the procedure by firmly retracting the controller wire. Other methods of deployment of DPRD and/or FRM may be used.


Reference is now made to FIG. 14, which illustrates a method of delivering a DPRD and/or an FRM into a body area, for example, the septum of the heart between the left and right atrium, according to some embodiments of the present invention. Implantation of a device in the septum may involve one or more of the following processes: a) identifying the precise site for imputation; b) aiming the device toward the selected site; and c) ensuring accuracy and integrity of the implantation. The ideal implantation position may be chosen, for example, by a medical professional, for example, by imaging the septum and analyzing the septum anatomy (e.g., by TEE). The aiming may include identifying the precise device delivery tool location using known tools for ‘mapping’ the septum site. Markers may be added to the delivery tools and devices (e.g., gold markers). Once the position has been identified, and the device has been deployed, the medical professional may check and test the device installation, optionally before full retrieval of the delivery system. For example, the medical professional may use direct contact such as physically challenging or pulling the entire device (e.g., by pulling gently on the device to ensure proper anchoring). The anchoring may be tested by non-contact means (e.g., using electromagnetic imaging, Echo, x-ray, angiography with contrast material, etc.).


At block 140 a DPRD may be implanted between two or more chambers, lumens, organs, regions, zones etc., in a body, for example, using a catheter. At block 141, an FRM may be deployed in a selected setting or position, for example, to enable a continuous flow of Quid between two or more lumens, and to be selectively activated or de-activated in accordance with changes in pressure differences between the lumens. At block 142, the FRM may be controlled (e.g., passively) in response to changes in pressure differences between the lumens, for example, FRM may be further opened and/or closed in response to a pressure change. Optionally, at block 143 the DPRD and/or FRM may be remotely controlled to help control the flow of fluids between the lumens. In some embodiments, the remote control of the DPRD and/or FRM may enable cleaning the DPRD and/or FRM, disabling the DPRD and/or FRM, changing elements of the DPRD and/or FRM, etc. Any combination of the above steps may be implemented. Further, other steps or series of steps may be used.


The foregoing description of the embodiments of the invention has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. It should be appreciated by persons skilled in the art that many modifications, variations, substitutions, changes, and equivalents are possible in light of the above teaching. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fell within the true spirit of the invention.

Claims
  • 1. A device for implantation within an atrial septum to treat a heart condition, the device comprising: a shunt configured to transition from a collapsed delivery state to an expanded deployed state, the shunt comprising a tubular body configured to be implanted in an opening in the atrial septum in the expanded deployed state such that the tubular body contacts the atrial septum, the shunt further comprising an inner shunt portion at least partially disposed within the tubular body, the inner shunt portion defining a continuously open passageway to permit blood to flow through the atrial septum via the continuously open passageway, the inner shunt portion having a constriction in a mid-region such that a cross-sectional area of the continuously open passageway is smallest at the constriction.
  • 2. The device of claim 1, wherein the shunt is configured to permit passage of blood through the atrial septum to unload an excessive filling pressure of a left ventricle in a patient with congestive heart failure.
  • 3. The device of claim 1, wherein the shunt is configured to permit passage of blood through the atrial septum in an amount sufficient to treat pulmonary hypertension.
  • 4. The device of claim 1, wherein the cross-sectional area of the continuously open passageway is from 3.5 mm2 to 24 mm2 for blood flow through the shunt.
  • 5. The device of claim 1, wherein the shunt is configured to provide enhanced blood flow across the atrial septum via the continuously open passageway when the interatrial pressure gradient ranges from greater than a threshold between 0 and 25 mmHg.
  • 6. The device of claim 1, wherein the cross-sectional area of the continuously open passageway is dependent on blood pressure differential across the atrial septum such that blood flow through the shunt changes responsive to change in the blood pressure differential across the atrial septum.
  • 7. The device of claim 1, wherein the cross-sectional area of the continuously open passageway is adjustable such that blood flow across the atrial septum through the continuously open passageway of the shunt is adjustable.
  • 8. The device of claim 7, wherein the cross-sectional area of the continuously open passageway is configured to be expanded to permit more blood flow across the atrial septum.
  • 9. The device of claim 7, wherein the cross-sectional area of the continuously open passageway is configured to be contracted to permit less blood flow across the atrial septum.
  • 10. The device of claim 7, wherein the shunt comprises a flexible metal.
  • 11. The device of claim 10, wherein the flexible metal comprises Nitinol.
  • 12. The device of claim 7, wherein the shunt comprises a shape-memory material.
  • 13. The device of claim 12, wherein the shunt further comprises a super elastic alloy.
  • 14. The device of claim 7, wherein the shunt is configured to self-expand from the collapsed delivery state to the expanded deployed state.
  • 15. The device of claim 7, further comprising an actuation element configured to be actuated to cause the cross-sectional area of the continuously open passageway to be expanded or contracted.
  • 16. The device of claim 15, wherein the actuation element comprises a spring-type mechanism to expand or contract the inner shunt portion.
  • 17. The device of claim 7, wherein the inner shunt portion comprises a flexible membrane configured to be expanded and contracted.
  • 18. The device of claim 17, wherein the flexible membrane includes at least one spring-type mechanism to expand and/or contract the flexible membrane.
  • 19. The device of claim 7, wherein the shunt is configured to be controlled responsive to localized heating.
  • 20. The device of claim 7, wherein the cross-sectional area of the continuously open passageway is adjustable independent of the tubular body's diameter.
  • 21. The device of claim 20, wherein the cross-sectional area of the continuously open passageway is adjustable while the tubular body's diameter stays the same.
  • 22. The device of claim 20, wherein the tubular body remains contacted to, and anchored to, the atrial septum when the continuously open passageway of the inner shunt portion is adjusted.
  • 23. The device of claim 1, wherein the shunt is configured to protrude into at least one of a right atrium or a left atrium of the patient in the expanded deployed state.
  • 24. The device of claim 1, wherein the shunt comprises a coating to increase bio-compatibility.
  • 25. The device of claim 1, further comprising an anchor for retaining the shunt in the opening in the atrial septum in the expanded deployed state.
  • 26. The device of claim 1, wherein the inner shunt portion comprises a first section joined to a second section, wherein each of the first and second sections has a first end and a second end and the first ends of both the first and second sections meet at the constriction in the mid-region, and wherein the first and second sections each have diameters that gradually increase with distance from the first end towards the second end.
  • 27. A method for treating a heart condition, the method comprising: delivering a shunt within a puncture of an atrial septum of a patient's heart in a collapsed delivery state; andtransitioning the shunt from the collapsed delivery state to an expanded deployed state within the atrial septum such that a tubular body of the shunt is implanted in the puncture in the atrial septum in the expanded deployed state such that the tubular body contacts the atrial septum, the shunt further comprising an inner shunt portion at least partially disposed within the tubular body, the inner shunt portion defining a continuously open passageway to permit blood to flow through the atrial septum via the continuously open passageway, the inner shunt portion having a constriction in a mid-region such that a cross-sectional area of the continuously open passageway is smallest at the constriction.
  • 28. The method of claim 27, further comprising adjusting the cross-sectional area of the continuously open passageway such that blood flow across the atrial septum is adjustable.
  • 29. The method of claim 28, further comprising controlling the shunt via localized heating.
  • 30. The method of claim 27, wherein transitioning the shunt from the collapsed delivery state to the expanded deployed state within the atrial septum comprises: advancing a delivery catheter mounted to the shunt in the collapsed delivery state through a sheath positioned within the puncture of the atrial septum until a first end of the shunt self-expands within a first atrium of the patient's heart; andretracting the sheath relative to the atrial septum until a second end of the shunt self-expands within a second atrium of the patient's heart.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/672,420, filed Nov. 1, 2019, now U.S. Pat. No. 11,266,501, which is a continuation of U.S. patent application Ser. No. 15/668,622, filed Aug. 3, 2017, now U.S. Pat. No. 10,463,490, which is a divisional application of U.S. patent application Ser. No. 13/108,672, filed May 16, 2011, now U.S. Pat. No. 9,724,499, which is a continuation under 35 U.S.C. § 120 of U.S. patent application Ser. No. 10/597,666, filed Jun. 20, 2007, now U.S. Pat. No. 8,070,708, and entitled “Device and Method for Controlling In-Vivo Pressure,” which is a U.S. national stage filing under 35 U.S.C. § 371 of international Patent Application No. PCT/IL2005/000131, filed Feb. 3, 2005, which claims the benefit of U.S. Provisional Patent Application No. 60/573,378, filed May 24, 2004, and U.S. Provisional Patent Application No. 60/541,267, filed Feb. 3, 2004, the entire contents of each of which are incorporated by reference herein.

US Referenced Citations (512)
Number Name Date Kind
3852334 Dusza et al. Dec 1974 A
3874388 King et al. Apr 1975 A
3952334 Bokros et al. Apr 1976 A
4484955 Hochstein Nov 1984 A
4601309 Chang Jul 1986 A
4617932 Kornberg Oct 1986 A
4662355 Pieronne et al. May 1987 A
4665906 Jervis May 1987 A
4705507 Boyles Nov 1987 A
4836204 Landymore et al. Jun 1989 A
4979955 Smith Dec 1990 A
4988339 Vadher Jan 1991 A
4995857 Arnold Feb 1991 A
5035702 Taheri Jul 1991 A
5035706 Giantureo et al. Jul 1991 A
5037427 Harada et al. Aug 1991 A
5089005 Harada Feb 1992 A
5186431 Tamari Feb 1993 A
5197978 Hess Mar 1993 A
5234447 Kaster et al. Aug 1993 A
5267940 Moulder Dec 1993 A
5290227 Pasque Mar 1994 A
5312341 Turi May 1994 A
5326374 Ilbawi et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5334217 Das Aug 1994 A
5378239 Termin et al. Jan 1995 A
5409019 Wilk Apr 1995 A
5429144 Wilk Jul 1995 A
5500015 Deac Mar 1996 A
5531759 Kensey et al. Jul 1996 A
5545210 Hess et al. Aug 1996 A
5556386 Todd Sep 1996 A
5578008 Hara Nov 1996 A
5584803 Stevens et al. Dec 1996 A
5597377 Aldea Jan 1997 A
5645559 Hachtman et al. Jul 1997 A
5655548 Nelson et al. Aug 1997 A
5662711 Douglas Sep 1997 A
5702412 Popov et al. Dec 1997 A
5725552 Kotula et al. Mar 1998 A
5741324 Glastra Apr 1998 A
5749880 Banas et al. May 1998 A
5779716 Cano et al. Jul 1998 A
5795307 Krueger Aug 1998 A
5810836 Hussein et al. Sep 1998 A
5824062 Patke et al. Oct 1998 A
5824071 Nelson et al. Oct 1998 A
5846261 Kotula et al. Dec 1998 A
5910144 Hayashi Jun 1999 A
5916193 Stevens et al. Jun 1999 A
5941850 Shah et al. Aug 1999 A
5957949 Leonhardt et al. Sep 1999 A
5990379 Gregory Nov 1999 A
6027518 Gaber Feb 2000 A
6039755 Edwin et al. Mar 2000 A
6039759 Carpentier et al. Mar 2000 A
6086610 Duerig et al. Jul 2000 A
6111520 Allen et al. Aug 2000 A
6117159 Huebsch et al. Sep 2000 A
6120534 Ruiz Sep 2000 A
6124523 Banas et al. Sep 2000 A
6126686 Badylak et al. Oct 2000 A
6165188 Saadat et al. Dec 2000 A
6210318 Lederman Apr 2001 B1
6214039 Banas et al. Apr 2001 B1
6217541 Yu Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6242762 Brown et al. Jun 2001 B1
6245099 Edwin et al. Jun 2001 B1
6254564 Wilk et al. Jul 2001 B1
6260552 Mortier et al. Jul 2001 B1
6264684 Banas et al. Jul 2001 B1
6270515 Linden et al. Aug 2001 B1
6270526 Cox Aug 2001 B1
6277078 Porat et al. Aug 2001 B1
6278379 Allen et al. Aug 2001 B1
6302892 Wilk Oct 2001 B1
6306141 Jervis Oct 2001 B1
6328699 Eigler et al. Dec 2001 B1
6344022 Jarvik Feb 2002 B1
6358277 Duran Mar 2002 B1
6391036 Berg et al. May 2002 B1
6398803 Layne et al. Jun 2002 B1
6406422 Landesberg Jun 2002 B1
6447539 Nelson et al. Sep 2002 B1
6451051 Drasler et al. Sep 2002 B2
6458153 Bailey et al. Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6475136 Forsell Nov 2002 B1
6478776 Rosenman et al. Nov 2002 B1
6485507 Walak et al. Nov 2002 B1
6488702 Besselink Dec 2002 B1
6491705 Gifford, III et al. Dec 2002 B2
6527698 Kung et al. Mar 2003 B1
6544208 Ethier et al. Apr 2003 B2
6547814 Edwin et al. Apr 2003 B2
6562066 Martin May 2003 B1
6572652 Shaknovich Jun 2003 B2
6579314 Lombardi et al. Jun 2003 B1
6589198 Soltanpour et al. Jul 2003 B1
6616675 Evard et al. Sep 2003 B1
6632169 Korakianitis et al. Oct 2003 B2
6638303 Campbell Oct 2003 B1
6641610 Wolf et al. Nov 2003 B2
6652578 Bailey et al. Nov 2003 B2
6685664 Levin et al. Feb 2004 B2
6712836 Berg et al. Mar 2004 B1
6740115 Lombardi et al. May 2004 B2
6758858 McCrea et al. Jul 2004 B2
6764507 Shanley et al. Jul 2004 B2
6770087 Layne et al. Aug 2004 B2
6797217 McCrea et al. Sep 2004 B2
6890350 Walak May 2005 B1
6923829 Boyle et al. Aug 2005 B2
6970742 Mann et al. Nov 2005 B2
7001409 Amplatz Feb 2006 B2
7004966 Edwin et al. Feb 2006 B2
7025777 Moore Apr 2006 B2
7060150 Banas et al. Jun 2006 B2
7083640 Lombardi et al. Aug 2006 B2
7115095 Eigler et al. Oct 2006 B2
7118600 Dua et al. Oct 2006 B2
7137953 Eigler et al. Nov 2006 B2
7147604 Allen et al. Dec 2006 B1
7149587 Wardle et al. Dec 2006 B2
7169160 Middleman et al. Jan 2007 B1
7169172 Levine et al. Jan 2007 B2
7195594 Eigler et al. Mar 2007 B2
7208010 Shanley et al. Apr 2007 B2
7226558 Nieman et al. Jun 2007 B2
7245117 Joy et al. Jul 2007 B1
7294115 Wilk Nov 2007 B1
7306756 Edwin et al. Dec 2007 B2
7402899 Whiting et al. Jul 2008 B1
7439723 Allen et al. Oct 2008 B2
7468071 Edwin et al. Dec 2008 B2
7483743 Mann et al. Jan 2009 B2
7498799 Allen et al. Mar 2009 B2
7509169 Eigler et al. Mar 2009 B2
7550978 Joy et al. Jun 2009 B2
7578899 Edwin et al. Aug 2009 B2
7590449 Mann et al. Sep 2009 B2
7615010 Najafi et al. Nov 2009 B1
7621879 Eigler et al. Nov 2009 B2
7679355 Allen et al. Mar 2010 B2
7717854 Mann et al. May 2010 B2
7794473 Tessmer et al. Sep 2010 B2
7839153 Joy et al. Nov 2010 B2
7842083 Shanley et al. Nov 2010 B2
7854172 O'Brien et al. Dec 2010 B2
7862513 Eigler et al. Jan 2011 B2
7914639 Layne et al. Mar 2011 B2
7939000 Edwin et al. May 2011 B2
7988724 Salahieh et al. Aug 2011 B2
7993383 Hartley et al. Aug 2011 B2
8012194 Edwin et al. Sep 2011 B2
8016877 Seguin et al. Sep 2011 B2
8021420 Dolan Sep 2011 B2
8025625 Allen Sep 2011 B2
8025668 McCartney Sep 2011 B2
8043360 McNamara et al. Oct 2011 B2
8070708 Rottenberg et al. Dec 2011 B2
8091556 Keren et al. Jan 2012 B2
8096959 Stewart et al. Jan 2012 B2
8137605 McCrea et al. Mar 2012 B2
8142363 Eigler et al. Mar 2012 B1
8147545 Avior Apr 2012 B2
8157852 Bloom et al. Apr 2012 B2
8157860 McNamara et al. Apr 2012 B2
8157940 Edwin et al. Apr 2012 B2
8158041 Colone Apr 2012 B2
8187321 Shanley et al. May 2012 B2
8202313 Shanley et al. Jun 2012 B2
8206435 Shanley et al. Jun 2012 B2
8235916 Whiting et al. Aug 2012 B2
8235933 Keren et al. Aug 2012 B2
8246677 Ryan Aug 2012 B2
8287589 Otto et al. Oct 2012 B2
8298150 Mann et al. Oct 2012 B2
8298244 Garcia et al. Oct 2012 B2
8303511 Eigler et al. Nov 2012 B2
8313524 Edwin et al. Nov 2012 B2
8328751 Keren et al. Dec 2012 B2
8337650 Edwin et al. Dec 2012 B2
8348996 Tuval et al. Jan 2013 B2
8357193 Phan et al. Jan 2013 B2
8398708 Meiri et al. Mar 2013 B2
8460366 Rowe Jun 2013 B2
8468667 Straubinger et al. Jun 2013 B2
8480594 Eigler et al. Jul 2013 B2
8579966 Seguin et al. Nov 2013 B2
8597225 Kapadia Dec 2013 B2
8617337 Layne et al. Dec 2013 B2
8617441 Edwin et al. Dec 2013 B2
8652284 Bogert et al. Feb 2014 B2
8665086 Miller et al. Mar 2014 B2
8696611 Nitzan et al. Apr 2014 B2
8790241 Edwin et al. Jul 2014 B2
8882697 Celermajer et al. Nov 2014 B2
8882798 Schwab et al. Nov 2014 B2
8911489 Ben-Muvhar Dec 2014 B2
9005155 Sugimoto Apr 2015 B2
9034034 Nitzan et al. May 2015 B2
9055917 Mann et al. Jun 2015 B2
9060696 Eigler et al. Jun 2015 B2
9067050 Gallagher et al. Jun 2015 B2
9205236 McNamara et al. Dec 2015 B2
9220429 Nabutovsky et al. Dec 2015 B2
9358371 McNamara et al. Jun 2016 B2
9393115 Tabor et al. Jul 2016 B2
9456812 Finch et al. Oct 2016 B2
9622895 Cohen et al. Apr 2017 B2
9629715 Nitzan et al. Apr 2017 B2
9681948 Levi et al. Jun 2017 B2
9707382 Nitzan et al. Jul 2017 B2
9713696 Yacoby et al. Jul 2017 B2
9724499 Rottenberg et al. Aug 2017 B2
9757107 McNamara et al. Sep 2017 B2
9789294 Taft et al. Oct 2017 B2
9918677 Eigler et al. Mar 2018 B2
9943670 Keren et al. Apr 2018 B2
9980815 Nitzan et al. May 2018 B2
10045766 McNamara et al. Aug 2018 B2
10047421 Khan et al. Aug 2018 B2
10076403 Eigler et al. Sep 2018 B1
10105103 Goldshtein et al. Oct 2018 B2
10111741 Michalak Oct 2018 B2
10207087 Keren et al. Feb 2019 B2
10207807 Moran et al. Feb 2019 B2
10251740 Eigler et al. Apr 2019 B2
10251750 Alexander et al. Apr 2019 B2
10299687 Nabutovsky et al. May 2019 B2
10357320 Beira Jul 2019 B2
10357357 Levi et al. Jul 2019 B2
10368981 Nitzan et al. Aug 2019 B2
10463490 Rottenberg et al. Nov 2019 B2
10478594 Yacoby et al. Nov 2019 B2
10548725 Alkhatib et al. Feb 2020 B2
10561423 Sharma Feb 2020 B2
10639459 Nitzan et al. May 2020 B2
10828151 Nitzan et al. Nov 2020 B2
10835394 Nae et al. Nov 2020 B2
10898698 Eigler et al. Jan 2021 B1
10912645 Rottenberg et al. Feb 2021 B2
10925706 Eigler et al. Feb 2021 B2
10940296 Keren Mar 2021 B2
20010021872 Bailey et al. Sep 2001 A1
20020120277 Hauschild et al. Aug 2002 A1
20020165479 Wilk Nov 2002 A1
20020165606 Wolf et al. Nov 2002 A1
20020169371 Gilderdale Nov 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20020173742 Keren et al. Nov 2002 A1
20020183628 Reich et al. Dec 2002 A1
20030028213 Thill et al. Feb 2003 A1
20030045902 Weadock Mar 2003 A1
20030100920 Akin et al. May 2003 A1
20030125798 Martin Jul 2003 A1
20030136417 Fonseca et al. Jul 2003 A1
20030139819 Beer et al. Jul 2003 A1
20030176914 Rabkin et al. Sep 2003 A1
20030209835 Chun et al. Nov 2003 A1
20030216679 Wolf et al. Nov 2003 A1
20030216803 Ledergerber Nov 2003 A1
20040010219 McCusker et al. Jan 2004 A1
20040016514 Nien Jan 2004 A1
20040073242 Chanduszko Apr 2004 A1
20040077988 Tweden et al. Apr 2004 A1
20040088045 Cox May 2004 A1
20040093075 Kuehne May 2004 A1
20040102797 Golden et al. May 2004 A1
20040116999 Ledergerber Jun 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040147869 Wolf et al. Jul 2004 A1
20040147871 Burnett Jul 2004 A1
20040147886 Bonni Jul 2004 A1
20040147969 Mann et al. Jul 2004 A1
20040162514 Alferness et al. Aug 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040210190 Kohler et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040225352 Osborne et al. Nov 2004 A1
20050003327 Elian et al. Jan 2005 A1
20050033327 Gainor et al. Feb 2005 A1
20050033351 Newton Feb 2005 A1
20050065589 Schneider et al. Mar 2005 A1
20050125032 Whisenant et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050148925 Rottenberg et al. Jul 2005 A1
20050165344 Dobak, III Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050267524 Chanduszko Dec 2005 A1
20050283231 Haug et al. Dec 2005 A1
20050288596 Eigler et al. Dec 2005 A1
20050288706 Widomski et al. Dec 2005 A1
20050288786 Chanduszko Dec 2005 A1
20060009800 Christianson et al. Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060111660 Wolf et al. May 2006 A1
20060116710 Corcoran et al. Jun 2006 A1
20060122522 Chavan et al. Jun 2006 A1
20060122647 Callaghan et al. Jun 2006 A1
20060167541 Lattouf Jul 2006 A1
20060184231 Rucker Aug 2006 A1
20060212110 Osborne et al. Sep 2006 A1
20060241745 Solem Oct 2006 A1
20060256611 Bednorz et al. Nov 2006 A1
20060282157 Hill et al. Dec 2006 A1
20070010852 Blaeser et al. Jan 2007 A1
20070021739 Weber Jan 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070129756 Abbott et al. Jun 2007 A1
20070191863 De Juan, Jr. et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070276413 Nobles Nov 2007 A1
20070276414 Nobles Nov 2007 A1
20070282157 Rottenberg et al. Dec 2007 A1
20070299384 Faul et al. Dec 2007 A1
20080034836 Eigler et al. Feb 2008 A1
20080086205 Gordy et al. Apr 2008 A1
20080125861 Webler et al. May 2008 A1
20080177300 Mas et al. Jul 2008 A1
20080262602 Wilk et al. Oct 2008 A1
20080319525 Tieu et al. Dec 2008 A1
20090030499 Bebb et al. Jan 2009 A1
20090054976 Tuval et al. Feb 2009 A1
20090125104 Hoffman May 2009 A1
20090149947 Frohwitter Jun 2009 A1
20090198315 Boudjemline Aug 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100004740 Seguin et al. Jan 2010 A1
20100022940 Thompson Jan 2010 A1
20100057192 Celermajer Mar 2010 A1
20100069836 Satake Mar 2010 A1
20100070022 Kuehling Mar 2010 A1
20100081867 Fishler et al. Apr 2010 A1
20100100167 Bortlein et al. Apr 2010 A1
20100121434 Paul et al. May 2010 A1
20100179590 Fortson et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100249909 McNamara et al. Sep 2010 A1
20100249910 McNamara et al. Sep 2010 A1
20100249915 Zhang Sep 2010 A1
20100256548 McNamara et al. Oct 2010 A1
20100256753 McNamara et al. Oct 2010 A1
20100298755 McNamara et al. Nov 2010 A1
20110022057 Eigler et al. Jan 2011 A1
20110022157 Essinger et al. Jan 2011 A1
20110054515 Bridgeman et al. Mar 2011 A1
20110071623 Finch et al. Mar 2011 A1
20110071624 Finch et al. Mar 2011 A1
20110093059 Fischell et al. Apr 2011 A1
20110152923 Fox Jun 2011 A1
20110190874 Celermajer et al. Aug 2011 A1
20110218479 Rottenberg et al. Sep 2011 A1
20110218480 Rottenberg et al. Sep 2011 A1
20110218481 Rottenberg et al. Sep 2011 A1
20110257723 McNamara Oct 2011 A1
20110264203 Dwork et al. Oct 2011 A1
20110276086 Al-Qbandi et al. Nov 2011 A1
20110295182 Finch et al. Dec 2011 A1
20110295183 Finch et al. Dec 2011 A1
20110295362 Finch et al. Dec 2011 A1
20110295366 Finch et al. Dec 2011 A1
20110306916 Nitzan et al. Dec 2011 A1
20110319806 Wardle Dec 2011 A1
20120022507 Najafi et al. Jan 2012 A1
20120022633 Olson et al. Jan 2012 A1
20120035590 Whiting et al. Feb 2012 A1
20120041422 Whiting et al. Feb 2012 A1
20120046528 Eigler et al. Feb 2012 A1
20120046739 Von Oepen et al. Feb 2012 A1
20120053686 McNamara et al. Mar 2012 A1
20120071918 Amin et al. Mar 2012 A1
20120130301 McNamara et al. May 2012 A1
20120165928 Nitzan et al. Jun 2012 A1
20120179172 Paul, Jr. et al. Jul 2012 A1
20120190991 Bornzin et al. Jul 2012 A1
20120265296 McNamara et al. Oct 2012 A1
20120271398 Essinger et al. Oct 2012 A1
20120289882 McNamara et al. Nov 2012 A1
20120290062 McNamara et al. Nov 2012 A1
20130030521 Nitzan et al. Jan 2013 A1
20130046373 Cartledge et al. Feb 2013 A1
20130138145 Von Oepen May 2013 A1
20130178783 McNamara et al. Jul 2013 A1
20130178784 McNamara et al. Jul 2013 A1
20130184633 McNamara et al. Jul 2013 A1
20130184634 McNamara et al. Jul 2013 A1
20130197423 Keren et al. Aug 2013 A1
20130197547 Fukuoka et al. Aug 2013 A1
20130197629 Gainor et al. Aug 2013 A1
20130204175 Sugimoto Aug 2013 A1
20130231737 McNamara et al. Sep 2013 A1
20130261531 Gallagher et al. Oct 2013 A1
20130281988 Magnin et al. Oct 2013 A1
20130304192 Chanduszko Nov 2013 A1
20140012181 Sugimoto et al. Jan 2014 A1
20140012303 Heipl Jan 2014 A1
20140012368 Sugimoto et al. Jan 2014 A1
20140012369 Murry, III et al. Jan 2014 A1
20140067037 Fargahi Mar 2014 A1
20140094904 Salahieh et al. Apr 2014 A1
20140128795 Keren et al. May 2014 A1
20140128796 Keren et al. May 2014 A1
20140163449 Rottenberg et al. Jun 2014 A1
20140194971 McNamara Jul 2014 A1
20140213959 Nitzan et al. Jul 2014 A1
20140222144 Eberhardt et al. Aug 2014 A1
20140249621 Eidenschink Sep 2014 A1
20140257167 Celermajer Sep 2014 A1
20140275916 Nabutovsky et al. Sep 2014 A1
20140277045 Fazio et al. Sep 2014 A1
20140277054 McNamara et al. Sep 2014 A1
20140303710 Zhang et al. Oct 2014 A1
20140350565 Yacoby et al. Nov 2014 A1
20140350658 Benary et al. Nov 2014 A1
20140350661 Schaeffer Nov 2014 A1
20140350669 Gillespie et al. Nov 2014 A1
20140357946 Golden et al. Dec 2014 A1
20150005810 Center et al. Jan 2015 A1
20150034217 Vad Feb 2015 A1
20150039084 Levi et al. Feb 2015 A1
20150066140 Quadri et al. Mar 2015 A1
20150073539 Geiger et al. Mar 2015 A1
20150112383 Sherman et al. Apr 2015 A1
20150119796 Finch Apr 2015 A1
20150127093 Hosmer et al. May 2015 A1
20150142049 Delgado et al. May 2015 A1
20150148731 McNamara et al. May 2015 A1
20150148896 Karapetian et al. May 2015 A1
20150157455 Hoang et al. Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150182334 Bourang et al. Jul 2015 A1
20150190229 Seguin Jul 2015 A1
20150196383 Johnson Jul 2015 A1
20150201998 Roy et al. Jul 2015 A1
20150209143 Duffy et al. Jul 2015 A1
20150230924 Miller et al. Aug 2015 A1
20150238314 Bortlein et al. Aug 2015 A1
20150245908 Nitzan et al. Sep 2015 A1
20150272731 Racchini et al. Oct 2015 A1
20150282790 Quinn et al. Oct 2015 A1
20150282931 Brunnett et al. Oct 2015 A1
20150313599 Johnson et al. Nov 2015 A1
20150359556 Vardi Dec 2015 A1
20160007924 Eigler et al. Jan 2016 A1
20160022423 McNamara et al. Jan 2016 A1
20160022970 Forcucci et al. Jan 2016 A1
20160073907 Nabutovsky et al. Mar 2016 A1
20160120550 McNamara et al. May 2016 A1
20160129260 Mann et al. May 2016 A1
20160157862 Hernandez et al. Jun 2016 A1
20160166381 Sugimoto et al. Jun 2016 A1
20160184561 McNamara et al. Jun 2016 A9
20160206423 O'Connor et al. Jul 2016 A1
20160213467 Backus et al. Jul 2016 A1
20160220360 Lin et al. Aug 2016 A1
20160220365 Backus et al. Aug 2016 A1
20160262878 Backus et al. Sep 2016 A1
20160262879 Meiri et al. Sep 2016 A1
20160287386 Alon et al. Oct 2016 A1
20160296325 Edelman et al. Oct 2016 A1
20160361167 Tuval et al. Dec 2016 A1
20160361184 Tabor et al. Dec 2016 A1
20170035435 Amin et al. Feb 2017 A1
20170113026 Finch Apr 2017 A1
20170128705 Forcucci et al. May 2017 A1
20170135685 McNamara et al. May 2017 A9
20170165532 Khan Jun 2017 A1
20170216025 Nitzan et al. Aug 2017 A1
20170224323 Rowe et al. Aug 2017 A1
20170224444 Viecilli et al. Aug 2017 A1
20170231766 Hariton et al. Aug 2017 A1
20170273790 Vettukattil et al. Sep 2017 A1
20170281339 Levi et al. Oct 2017 A1
20170312486 Nitzan et al. Nov 2017 A1
20170319823 Yacoby et al. Nov 2017 A1
20170325956 Rottenberg et al. Nov 2017 A1
20170340460 Rosen et al. Nov 2017 A1
20170348100 Lane et al. Dec 2017 A1
20180099128 McNamara et al. Apr 2018 A9
20180104053 Alkhatib et al. Apr 2018 A1
20180125630 Hynes et al. May 2018 A1
20180130988 Nishikawa et al. May 2018 A1
20180243071 Eigler et al. Aug 2018 A1
20180256865 Finch et al. Sep 2018 A1
20180263766 Nitzan et al. Sep 2018 A1
20180280667 Keren Oct 2018 A1
20180344994 Karavany et al. Dec 2018 A1
20190000327 Doan et al. Jan 2019 A1
20190008628 Eigler et al. Jan 2019 A1
20190015103 Sharma Jan 2019 A1
20190015188 Eigler et al. Jan 2019 A1
20190021861 Finch Jan 2019 A1
20190110911 Nae et al. Apr 2019 A1
20190239754 Nabutovsky et al. Aug 2019 A1
20190254814 Nitzan et al. Aug 2019 A1
20190262118 Eigler et al. Aug 2019 A1
20190328513 Levi et al. Oct 2019 A1
20190336163 McNamara et al. Nov 2019 A1
20200060825 Rottenberg et al. Feb 2020 A1
20200078196 Rosen et al. Mar 2020 A1
20200078558 Yacoby et al. Mar 2020 A1
20200085600 Schwartz et al. Mar 2020 A1
20200197178 Vecchio Jun 2020 A1
20200261705 Nitzan et al. Aug 2020 A1
20200315599 Nae et al. Oct 2020 A1
20200368505 Nae et al. Nov 2020 A1
20210052378 Nitzan et al. Feb 2021 A1
Foreign Referenced Citations (37)
Number Date Country
2003291117 Apr 2009 AU
2378920 Feb 2001 CA
2238933 Oct 2010 EP
2305321 Apr 2011 EP
1965842 Nov 2011 EP
3400907 Nov 2018 EP
2827153 Jan 2003 FR
WO-9531945 Nov 1995 WO
WO-9727898 Aug 1997 WO
WO-9960941 Dec 1999 WO
WO-0044311 Aug 2000 WO
WO-0050100 Aug 2000 WO
WO-0110314 Feb 2001 WO
WO-0226281 Apr 2002 WO
WO-02071974 Sep 2002 WO
WO-02087473 Nov 2002 WO
WO-03053495 Jul 2003 WO
WO-2005027752 Mar 2005 WO
WO-2005074367 Aug 2005 WO
WO-2006127765 Nov 2006 WO
WO-2007083288 Jul 2007 WO
WO-2008055301 May 2008 WO
WO-2009029261 Mar 2009 WO
WO-2010128501 Nov 2010 WO
WO-2010129089 Nov 2010 WO
WO-2011062858 May 2011 WO
WO-2013096965 Jun 2013 WO
WO-2016178171 Nov 2016 WO
WO-2017118920 Jul 2017 WO
WO-2018158747 Sep 2018 WO
WO-2019015617 Jan 2019 WO
WO-2019085841 May 2019 WO
WO-2019109013 Jun 2019 WO
WO-2019142152 Jul 2019 WO
WO-2019179447 Sep 2019 WO
WO-2019218072 Nov 2019 WO
WO-2021050589 Mar 2021 WO
Non-Patent Literature Citations (297)
Entry
U.S. Appl. No. 09/839,643 / U.S. Pat. No. 8,091,556, filed Apr. 20, 2001 / Jan. 10, 2012.
U.S. Appl. No. 10/597,666 / U.S. Pat. No. 8,070,708, filed Jun. 20, 2007 / Dec. 6, 2011.
U.S. Appl. No. 12/223,080 / U.S. Pat. No. 9,681,948, filed Jul. 16, 2014 / Jun. 20, 2017.
U.S. Appl. No. 13/107,832 / U.S. Pat. No. 8,235,933, filed May 13, 2011 / Aug. 7, 2012.
U.S. Appl. No. 13/107,843 / U.S. Pat. No. 8,328,751, filed May 13, 2011 / Dec. 11, 2012.
U.S. Appl. No. 13/108,672 / U.S. Pat. No. 9,724,499, filed May 16, 2011 / Aug. 8, 2017.
U.S. Appl. No. 13/108,698, filed Jun. 16, 2011.
U.S. Appl. No. 13/108,850, filed May 16, 2011.
U.S. Appl. No. 13/108,880 / U.S. Pat. No. 8,696,611, filed May 16, 2011 / Apr. 15, 2014.
U.S. Appl. No. 13/193,309 / U.S. Pat. No. 9,629,715, filed Jul. 28, 2011 / Apr. 25, 2017.
U.S. Appl. No. 13/193,335 / U.S. Pat. No. 9,034,034, filed Jul. 28, 2011 / May 19, 2015.
U.S. Appl. No. 13/708,794 / U.S. Pat. No. 9,943,670, filed Dec. 7, 2012 / Apr. 17, 2018.
U.S. Appl. No. 14/154,080 / U.S. Pat. No. 10,207,807, filed Jan. 13, 2014 / Feb. 19, 2019.
U.S. Appl. No. 14/154,088, filed Jan. 13, 2014.
U.S. Appl. No. 14/154,093, filed Jan. 13, 2014.
U.S. Appl. No. 14/227,982 / U.S. Pat. No. 9,707,382, filed Mar. 27, 2014 / Jul. 18, 2017.
U.S. Appl. No. 14/282,615 / U.S. Pat. No. 9,713,696, filed May 20, 2014 / Jul. 25, 2017.
U.S. Appl. No. 14/712,801 / U.S. Pat. No. 9,980,815, filed May 14, 2015 / May 29, 2018.
U.S. Appl. No. 15/449,834 / U.S. Pat. No. 10,076,403, filed Mar. 3, 2017 / Sep. 18, 2018.
U.S. Appl. No. 15/492,852 / U.S. Pat. No. 10,368,981, filed Apr. 20, 2017 / Aug. 6, 2019.
U.S. Appl. No. 15/570,752 / U.S. Pat. No. 10,940,296, filed Oct. 31, 2017 / Mar. 9, 2021.
U.S. Appl. No. 15/608,948, filed May 30, 2017.
U.S. Appl. No. 15/624,314 / U.S. Pat. No. 10,357,357, filed Jun. 15, 2017 / Jul. 23, 2019.
U.S. Appl. No. 15/650,783 / U.S. Pat. No. 10,639,459, filed Jul. 14, 2017 / May 5, 2020.
U.S. Appl. No. 15/656,936 / U.S. Pat. No. 10,478,594, filed Jul. 21, 2017 / Nov. 19, 2019.
U.S. Appl. No. 15/668,622 / U.S. Pat. No. 10,463,490, filed Aug. 3, 2017 / Nov. 5, 2019.
U.S. Appl. No. 15/798,250 / U.S. Pat. No. 11,109,988, filed Oct. 30, 2017 / Sep. 7, 2021.
U.S. Appl. No. 15/988,888 / U.S. Pat. No. 10,828,151, filed May 24, 2018 / Nov. 10, 2020.
U.S. Appl. No. 16/130,978 / U.S. Pat. No. 10,251,740, filed Sep. 13, 2018 / Apr. 9, 2019.
U.S. Appl. No. 16/130,988 / U.S. Pat. No. 10,925,706, filed Sep. 13, 2018 / Feb. 23, 2021.
U.S. Appl. No. 16/205,213 / U.S. Pat. No. 10,835,394, filed Nov. 29, 2018 / Nov. 17, 2020.
U.S. Appl. No. 16/374,698, filed Apr. 3, 2019.
U.S. Appl. No. 16/395,209 / U.S. Pat. No. 11,135,054, filed Apr. 25, 2019 / Oct. 5, 2021.
U.S. Appl. No. 16/408,419, filed May 9, 2019.
U.S. Appl. No. 16/505,624 / U.S. Pat. No. 11,253,353, filed Jul. 8, 2019 / Feb. 22, 2022.
U.S. Appl. No. 16/672,420 / U.S. Pat. No. 11,266,501, filed Nov. 1, 2019 / Mar. 8, 2022.
U.S. Appl. No. 16/686,013, filed Nov. 15, 2019.
U.S. Appl. No. 16/866,377, filed May 4, 2020.
U.S. Appl. No. 16/875,652 / U.S. Pat. No. 10,898,698, filed May 15, 2020 / Jan. 26, 2021.
U.S. Appl. No. 16/876,640, filed May 18, 2020.
U.S. Appl. No. 16/878,228 / U.S. Pat. No. 10,912,645, filed May 19, 2020 / Feb. 9, 2021.
U.S. Appl. No. 16/693,139, filed Jul. 17, 2020.
U.S. Appl. No. 17/092,063, filed Nov. 6, 2020.
U.S. Appl. No. 17/092,081, filed Nov. 6, 2020.
U.S. Appl. No. 17/095,615, filed Nov. 11, 2020.
U.S. Appl. No. 17/098,251 / U.S. Pat. No. 11,234,702, filed Nov. 13, 2020 / Feb. 1, 2022.
U.S. Appl. No. 17/166,771, filed Feb. 3, 2021.
U.S. Appl. No. 17/175,549, filed Feb. 12, 2021.
U.S. Appl. No. 17/192,612, filed Mar. 4, 2021.
U.S. Appl. No. 17/465,791, filed Sep. 2, 2021.
U.S. Appl. No. 17/490,510, filed Sep. 30, 2021.
U.S. Appl. No. 17/600,079, filed Sep. 29, 2021.
U.S. Appl. No. 17/649,176, filed Jan. 27, 2022.
U.S. Appl. No. 17/649,331, filed Jan. 28, 2022.
U.S. Appl. No. 17/651,409, filed Feb. 16, 2022.
Abraham et al., “Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial,” J Card Failure, 22:940 (2016) (Abstract Only).
Abraham et al., “Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial,” The Lancet, doi.org/10.1016/S0140-6736(15)00723-0 (2015).
Abraham et al., “Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial,” The Lancet, DOI:10.1016/S0140-6736(11)60101-3 (2011).
Abreu et al., “Doppler ultrasonography of the femoropopliteal segment in patients with venous ulcer,” J Vasc Bras., 11(4):277-285 (2012).
Adamson et al., “Ongoing Right Ventricular Hemodynamics in Heart Failure Clinical Value of Measurements Derived From an Implantable Monitoring System,” J Am Coll Cardiol., 41(4):565-571 (2003).
Adamson et al., “Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction,” Circ Heart Fail., 7:935-944 (2014).
Ambrosy et al. “The Global Health and Economic Burden of Hospitalizations for Heart Failure,” J Am Coll Cardiol., 63:1123-1133 (2014).
Aminde et al., “Current diagnostic and treatment strategies for Lutembacher syndrome: the pivotal role of echocardiography,” Cardiovasc Diagn Ther., 5(2):122-132 (2015).
Anderas E. “Advanced MEMS Pressure Sensors Operating in Fluids,” Digital Comprehensive Summaries of Uppsala Dissertation from the Faculty of Science and Technology 933. Uppsala ISBN 978-91-554-8369-2 (2012).
Anderas et al., “Tilted c-axis Thin-Film Bulk Wave Resonant Pressure Sensors with Improved Sensitivity,” IEEE Sensors J., 12(8):2653-2654 (2012).
Ando, et al., Left ventricular decompression through a patent foramen ovale in a patient with hypertrophic cardiomyopathy: A case report, Cardiovascular Ultrasound, 2: 1-7 (2004).
Article 34 Amendments dated May 28, 2013 in Int'l PCT Patent Appl. Serial No. PCT/IB2012/001859 (0810).
Article 34 Amendments dated Nov. 27, 2012 in Int'l PCT Patent Appl. Serial No. PCT/IL2011/000958 (0710).
Ataya et al., “A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy,” J. Clin. Med., 5(12):114 (2016).
“Atrium Advanta V12, Balloon Expandable Covered Stent, Improving Patient Outcomes with An Endovascular Approach,” Brochure, 8 pages, Getinge (2017).
Bannan et al., “Characteristics of Adult Patients with Atrial Septal Defects Presenting with Paradoxical Embolism.,” Catheterization and Cardiovascular Interventions, 74:1066-1069 (2009).
Baumgartner et al., “ESC Guidelines for the management of grown-up congenital heart disease (new version 2010)—The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC),” Eur Heart J., 31:2915-2957 (2010).
Beemath et al., “Pulmonary Embolism as a Cause of Death in Adults Who Died With Heart Failure,” Am J Cardiol., 98:1073-1075 (2006).
Benza et al., “Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor,” Chest, 156(6):1176-1186 (2019).
Boehm, et al., “Balloon Atrial Septostomy: History and Technique,” Images Paeditr. Cardiol., 8(1):8-14(2006).
Braunwald, Heart Disease, Chapter 6, pp. 186.
Bridges, et al., “The Society of Thoracic Surgeons Practice Guideline Series: Transmyocardial Laser Revascularization,” Ann Thorac Surg., 77:1494-1502 (2004).
Bristow, et al., “Improvement in cardiac myocite function by biological effects of medical therapy: a new concept in the treatment of heart failure,” European Heart Journal, 16 (Suppl.F): 20-31 (1995).
Bruch et al., “Fenestrated Occluders for Treatment of ASD in Elderly Patients with Pulmonary Hypertension and/or Right Heart Failure,” J Interven Cardiol., 21(1):44-49 (2008).
Burkhoff et al., “Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers,” Am J Physiol Heart Circ Physiol., 289:H501-H512 (2005).
Butler et al. “Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials,” JAMA., 312(8):789-790 (2014).
Case, et al., “Relief of High Left-Atrial Pressure in Left-Ventricular Failure,” Lancet, (pp. 841-842), Oct. 17, 1964.
Chakko et al., “Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care,” Am J Medicine, 90:353-359 (1991) (Abstract Only).
Chang et al., “State-of-the-art and recent developments in micro/nanoscale pressure sensors for smart wearable devices and health monitoring systems,” Nanotechnology and Precision Engineering, 3:43-52 (2020).
Chen et al., “Continuous wireless pressure monitoring and mapping with ultra-small passive sensors for health monitoring and critical care,” Nature Communications, 5(1):1-10 (2014).
Chen et al., “National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008,” JAMA, 306(15):1669-1678 (2011).
Chiche et al., “Prevalence of patent foramen ovale and stroke in pulmonary embolism patients,” Eur Heart J., 34:P1142 (2013) (Abstract Only).
Chin et al., “The right ventricle in pulmonary hypertension,” Coron Artery Dis., 16(1):13-18 (2005) (Abstract Only).
Chun et al., “Lifetime Analysis of Hospitalizations and Survival of Patients Newly Admitted With Heart Failure,” Circ Heart Fail., 5:414-421 (2012).
Ciarka et al., “Atrial Septostomy Decreases Sympathetic Overactivity in Pulmonary Arterial Hypertension,” Chest, 131 (6):P1831-1837 (2007) (Abstract Only).
Cleland et al., “The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe—Part 1: patient characteristics and diagnosis,” Eur Heart J., 24:442-463 (2003).
Clowes et al., “Mechanisms of Arterial Graft Healing—Rapid Transmural Capillary Ingrowth Provides a Source of Intimal Endothelium and Smooth Muscle in Porous PTFE Prostheses,” Am J Pathol., 123:220-230 (1986).
Coats, et al., “Controlled Trial of Physical Training in Chronic Heart Failure: Exercise Performance, Hemodynamics, Ventilation, and Autonomic Function,” Circulation, 85: 2119-2131 (1992).
Davies et al., “Abnormal left heart function after operation for atrial septal defect,” British Heart Journal, 32:747-753(1970).
Davies, et al., “Reduced Contraction and Altered Frequency Response of Isolated Ventricular Myocytes From Patients With Heart Failure, Circulation,” 92: 2540-2549 (1995).
Del Trigo et al., “Unidirectional Left-To-Right Interatrial Shunting for Treatment of Patients with Heart Failure with Reduced Ejection Fraction: a Safety and Proof-of-Principle Cohort Study,” Lancet, 387:1290-1297 (2016).
Della Lucia et al., “Design, fabrication and characterization of SAW pressure sensors for offshore oil and gas exploration,” Sensors and Actuators A: Physical, 222:322-328 (2015).
Drazner et al., “Prognostic Importance of Elevated Jugular Venous Pressure and a Third Heart Sound in Patients with Heart Failure,” N Engl J Med., 345(8):574-81 (2001).
Drazner et al., “Relationship between Right and Left-Sided Filling Pressures in 1000 Patients with Advanced Heart Failure,” Heart Lung Transplant, 18:1126-1132 (1999).
Drexel, et al., “The Effects of Cold Work and Heat Treatment on the Properties of Nitinol Wire, Proceedings of the International Conference on Shape Memory and Superelastic Technologies, SMST 2006,” Pacific Grove, California, USA (pp. 447-454) May 7-11, 2006.
Eigler et al., “Cardiac Unloading with an Implantable Interatrial Shunt in Heart Failure: Serial Observations in an Ovine Model of Ischemic Cardiomyopathy,” Structural Heart, 1:40-48 (2017).
Eigler, et al., Implantation and Recovery of Temporary Metallic Stents in Canine Coronary Arteries, JACC, 22(4):1207-1213 (1993).
Ennezat, et al., An unusual case of low-flow, low gradient severe aortic stenosis: Left-to-right shunt due to atrial septal defect, Cardiology, 113(2):146-148, (2009).
Eshaghian et al., “Relation of Loop Diuretic Dose to Mortality in Advanced Heart Failure,” Am J Cardiol., 97:1759-1764 (2006).
Ewert, et al., Acute Left Heart Failure After Interventional Occlusion of An Artial Septal Defect, Z Kardiol, 90(5): 362-366 (May 2001).
Ewert, et al., Masked Left Ventricular Restriction in Elderly Patients With Atrial Septal Defects: A Contraindication for Closure?, Catheterization and Cardiovascular Intervention, 52:177-180 (2001).
Extended European Search Report dated Jan. 8, 2015 in EP Patent Appl No. 10772089.8. (0530).
Extended European Search Report dated Mar. 29, 2019 in EP Patent Appl. Serial No. EP16789391 (1830).
Extended European Search Report dated Sep. 19, 2016 in EP Patent Appl. No. 16170281.6 (0731).
Feldman et al., “Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure with Preserved Ejection Fraction (Reduce LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]), A Phase 2, Randomized, Sham-Controlled Trial,” Circulation, 137:364-375 (2018).
Ferrari et al., “Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers: results from an international survey,” Eur Respir J., 42:26312 (2013) (Abstract Only).
Final Office Action dated Jan. 5, 2009 in related U.S. Appl. No. 10/597,666.
Final Office Action dated Jan. 7, 2010 in related U.S. Appl. No. 10/597,666.
Fonarow et al., “Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure,” J Am Coll Cardiol., 50(8):768-777 (2007).
Fonarow et al., “Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart Failure: Classification and Regression Tree Analysis,” JAMA, 293(5):572-580 (2005).
Fonarow, G., “The Treatment Targets in Acute Decompensated Heart Failure,” Rev Cardiovasc Med., 2:(2):S7-S12 (2001).
Galie et al., “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension—The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS),” European Heart Journal, 37:67-119 (2016).
Galie et al., “Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses,” Eur Heart J., 31:2080-2086 (2010).
Galipeau et al., “Surface acoustic wave microsensors and applications,” Smart Materials and Structures, 6(6):658-667 (1997) (Abstract Only).
Geiran, et al., Changes in cardiac dynamics by opening an interventricular shunt in dogs, J. Surg. Res. 48(1):6-12(1990).
Gelernter-Yaniv, et al., Transcatheter ClosureoOf Left-To-Right Interatrial Shunts to Resolve Hypoxemia, Congenit. Heart Dis. 31(1): 47-53 (Jan. 2008).
Geva et al., “Atrial septal defects,” Lancet, 383:1921-32 (2014).
Gewillig, et al., Creation with a stent of an unrestrictive lasting atrial communication, Cardio. Young 12(4): 404-407 (2002).
Gheorghiade et al., “Acute Heart Failure Syndromes, Current State and Framework for Future Research,” Circulation, 112:3958-3968 (2005).
Gheorghiade et al., “Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure A Randomized Controlled Trial,” JAMA., 291:1963-1971 (2004).
Go et al. “Heart Disease and Stroke Statistics—2014 Update—A Report From the American Heart Association,” Circulation, 128:1-267 (2014).
Guillevin et al., “Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives,” Eur Respir Rev., 22:535-542 (2013).
Guyton et al., “Effect of Elevated Left Atrial Pressure and Decreased Plasma Protein Concentration on the Development of Pulmonary Edema,” Circulation Research, 7:643-657 (1959).
Hasenfub, et al., A Transcatheter Intracardiac Shunt Device for Heart Failure with Preserved Ejection Fraction (Reduce LAP-HF): A Multicentre, Open-Label, Single-Arm, Phase 1 Trial, www.thelancet.com, 387:1298-1304 (2016).
Hoeper et al., “Definitions and Diagnosis of Pulmonary Hypertension,” J Am Coll Cardiol., 62(5):D42-D50 (2013).
Hogg et al., “Heart Failure With Preserved Left Ventricular Systolic Function. Epidemiology, Clinical Characteristics, and Prognosis,” J Am Coll Cardiol., 43(3):317-327 (2004).
Howell et al., “Congestive heart failure and outpatient risk of venous thromboembolism: A retrospective, case-control study,” Journal of Clinical Epidemiology, 54:810-816 (2001).
Huang et al., “Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses,” Am J Physiol Heart Circ Physiol., 286:H2141-H2150 (2004).
Humbert et al., “Pulmonary Arterial Hypertension in France—Results from a National Registry,” Am J Respir Crit Care Med., 173:1023-1030 (2006).
International Search Report & Written Opinion dated Nov. 7, 2016 in Int'l PCT Patent Appl. Serial No. PCT/IB2016/052561 (1810).
International Search Report & Written Opinion dated May 29, 2018 in Int'l PCT Patent Appl. Serial No. PCT/IB2018/051385 (1310).
International Search Report & Written Opinion dated Feb. 6, 2013 in Int'l PCT Patent Appl. No. PCT/IB2012/001859, 12 pages (0810).
International Search Report & Written Opinion dated Feb. 7, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2019/060257 (1410).
International Search Report & Written Opinion dated Feb. 9, 2022 in Int'l PCT Patent Appl. Serial No. PCT/IB2021/060473 (2010).
International Search Report & Written Opinion dated May 13, 2019 in Int'l PCT Patent Appl. No. PCT/IB2019/050452 (1610).
International Search Report & Written Opinion dated May 29, 2018 in Int'l PCT Patent Appl. Serial No. PCTIB2018/051355 (1310).
International Search Report & Written Opinion dated Jul. 14, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/053832 (1210).
International Search Report & Written Opinion dated Jul. 20, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/054699 (1710).
International Search Report & Written Opinion dated Jul. 23, 2021 in Int'l PCT Patent Appl. Serial No. PCT/IB2021/053594 (1910).
International Search Report & Written Opinion dated Aug. 12, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/053118 (1010).
International Search Report & Written Opinion dated Aug. 28, 2012 in Int'l PCT Patent Appl. No. PCT/IL2011/000958 (0710).
International Search Report & Written Opinion dated Sep. 21, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/054306 (1510).
International Search Report & Written Opinion dated Oct. 11, 2017 in Int'l PCT Patent Appl. Serial No. PCT/IB2017/053188 (1110).
International Search Report & Written Opinion dated Oct. 26, 2007 in Int'l PCT Patent Appl. Serial No. PCT/IB07/50234 (0610).
International Search Report dated Apr. 7, 2008 in Int'l PCT Patent Appl. Serial No. PCT/IL05/00131 (0410).
International Search Report dated Aug. 25, 2010 in Intl PCT Patent Appl. Serial No. PCT/IL2010/000354 (0510).
ISR & Written Opinion dated Feb. 16, 2015 in Int'l PCT Patent Appl. Serial No. PCT/IB2014/001771 (0910).
Jessup et al. “2009Focused Update: ACC/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation,” J. Am. Coll. Cardiol., 53:1343-1382 (2009).
Jiang, G., “Design challenges of implantable pressure monitoring system,” Frontiers in Neuroscience, 4(29):1-4 (2010).
Kane et al., “Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension,” Chest, 139(6):1285-1293 (2011) (Abstract Only).
Kaye et al., “Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure,” Journal of Cardiac Failure, 20(3): 212-221 (2014).
Kaye et al., “One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction,” Circulation: Heart Failure, 9(12):e003662 (2016).
Keogh et al., “Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension,” J Am Coll Cardiol., 54:S67-77 (2009).
Keren, et al. Methods and Apparatus for Reducing Localized Circulatory System Pressure,., Jan. 7, 2002 (pp. 16).
Khositseth et al., Transcatheter Amplatzer Device Closure of Atrial Septal Defect and Patent Foramen Ovale in Patients With Presumed Paradoxical Embolism, Mayo Clinic Proc., 79:35-41 (2004).
Kramer, et al., Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study, Circulation, 67(4): 807-816, 1983.
Kretschmar et al., “Shunt Reduction With a Fenestrated Amplatzer Device,” Catheterization and Cardiovascular Interventions, 76:564-571 (2010).
Kropelnicki et al., “CMOS-compatible ruggedized high-temperature Lamb wave pressure sensor,” J. Micromech. Microeng., 23:085018 pp. 1-9 (2013).
Krumholz et al., “Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission,” Circ Cardiovasc Qual Outcomes, 2:407-413 (2009).
Kulkarni et al., “Lutembacher's syndrome,” J Cardiovasc Did Res., 3(2):179-181 (2012).
Kurzyna et al., “Atrial Septostomy in Treatment of End-Stage Right Heart Failure in Patients With Pulmonary Hypertension,” Chest, 131:977-983 (2007).
Lai et al., Bidirectional Shunt Through a Residual Atrial Septal Defect After Percutaneous Transvenous Mitral Commissurotomy, Cadiology, 83(3): 205-207 (1993).
Lammers et al., “Efficacy and Long-Term Patency of Fenerstrated Amplatzer Devices in Children,” Catheter Cardiovasc Interv., 70:578-584 (2007).
Lemmer, et al., Surgical Implications of Atrial Septal Defect Complicating Aortic Balloon Valvuloplasty, Ann. thorac. Surg, 48(2):295-297 (Aug. 1989).
Lindenfeld et al. “Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline,” J. Cardiac Failure, 16(6):475-539 (2010).
Luo, Yi, Selective and Regulated RF Heating of Stent Toward Endohyperthermia Treatment of In-Stent Restenosis, A Thesis Submitted in Partial Fulfillment of The Requirements For The Degree of Master of Applied Science in The Faculty of Graduate and Postdoctoral Studies (Electrical and Computer Engineering), The University of British Columbia, Vancouver, Dec. 2014.
Macdonald et al., “Emboli Enter Penetrating Arteries of Monkey Brain in Relation to Their Size,” Stroke, 26:1247-1251 (1995).
Maluli et al., “Atrial Septostomy: A Contemporary Review,” Clin. Cardiol., 38(6):395-400 (2015).
Maurer et al., “Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF),” Journal of Cardiac Failure., 21(6): 479-488 (2015).
McClean et al., “Noninvasive Calibration of Cardiac Pressure Transducers in Patients With Heart Failure: An Aid to Implantable Hemodynamic Monitoring and Therapeutic Guidance,” J Cardiac Failure, 12(7):568-576 (2006).
McLaughlin et al., “Management of Pulmonary Arterial Hypertension,” J Am Coll Cardiol., 65(18):1976-1997 (2015).
McLaughlin et al., “Survival in Primary Pulmonary Hypertension—The Impact of Epoprostenol Therapy.,” Circulation, 106:1477-1482 (2002).
Merriam-Webster OnLine Dictionary, Definition of “chamber”, printed Dec. 20, 2004.
Mu et al., “Dual mode acoustic wave sensor for precise pressure reading,” Applied Physics Letters, 105:113507-1-113507-5 (2014).
Nagaraju et al., “A 400 μW Differential FBAR Sensor Interface IC with digital readout,” IEEE., pp. 218-221 (2015).
Non-Final Office Action dated Oct. 16, 2020 in U.S. Appl. No. 16/878,228 (0408).
Non-Final Office Action dated Oct. 28, 2021 in U.S. Appl. No. 16/62,420 (0407).
Non-Final Office Action dated Oct. 28, 2021 in U.S. Appl. No. 16/672,420 (0407).
Non-Final Office Action dated Nov. 21, 2018 in U.S. Appl. No. 15/668,622 (0406).
Noordegraaf et al., “The role of the right ventricle in pulmonary arterial hypertension,” Eur Respir Rev., 20(122):243-253 (2011).
Notice of Allowance dated Jan. 20, 2022 in U.S. Appl. No. 16/672,420 (0407).
Notice of Allowance dated Jun. 17, 2019 in U.S. Appl. No. 15/668,622 (0406).
Notice of Allowance dated Dec. 10, 2020 in U.S. Appl. No. 16/878,228 (0408).
O'Byrne et al., “The effect of atrial septostomy on the concentration of brain-type natriuretic peptide in patients with idiopathic pulmonary arterial hypertension,” Cardiology in the Young, 17(5):557-559 (2007) (Abstract Only).
Office Action dated Mar. 28, 2008 in related U.S. Appl. No. 10/597,666.
Oktay et al., “The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction,” Curr Heart Fail Rep., 10(4):1-17 (2013).
Owan et al., “Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction,” N Engl J Med., 355:251-259 (2006).
Paitazoglou et al., “Title: The AFR-Prelieve Trial: A prospective, non-randomized, pilot study to assess the Atrial Flow Regulator (AFR) in Heart Failure Patients with either preserved or reduced ejection fraction,” EuroIntervention, 28:2539-50 (2019).
Park Blade Septostomy Catheter Instructions for Use, Cook Medical, 28 pages, Oct. 2015.
Park, et al., Blade Atrial Septostomy: Collaborative Study, Circulation, 66(2):258-266 (1982).
Partial Supplemental European Search Report dated Dec. 11, 2018 in EP Patent Appl. Serial No. 16789391.6 (1830).
Peters et al., “Self-fabricated fenestrated Amplatzer occluders for transcatheter closure of atrial septal defect in patients with left ventricular restriction: midterm results,” Clin Res Cardiol., 95:88-92 (2006).
Ponikowski et al., “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC),” Eur Heart J., doi:10.1093/eurheartj/ehw128 (2016).
Potkay, J. A., “Long term, implantable blood pressure monitoring systems,” Biomed Microdevices, 10:379-392 (2008).
Preliminary Amendment dated May 18, 2020 in U.S. Appl. No. 16/672,420 (0407).
Preliminary Amendment dated Aug. 3, 2006 in related U.S. Appl. No. 10/597,666.
Preliminary Amendment dated Jan. 13, 2014 in related U.S. Appl. No. 14/154,093.
Preliminary Amendment dated Oct. 6, 2011 in related U.S. Appl. No. 13/108,672.
Preliminary Amendment dated Oct. 6, 2011 in related U.S. Appl. No. 13/108,850.
Pretorious et al., “An Implantable Left Atrial Pressure Sensor Lead Designed for Percutaneous Extraction Using Standard Techniques,” Pace, 00:1-8 (2013).
Rajeshkumar et al., “Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension,” Catheter Cardiovasc Interv., 1-9 (2017).
Response After Final Office Action dated Mar. 2, 2009 in U.S. Appl. No. 10/597,666.
Response dated Mar. 8, 2010 to Official Action dated Jan. 7, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/597,666.
Response Final Office Action dated Apr. 20, 2016 in related U.S. Appl. No. 13/108,698.
Response Final Office Action dated Apr. 20, 2016 in related U.S. Appl. No. 13/108,850.
Response Final Office Action dated Apr. 30, 2014 in related U.S. Appl. No. 13/108,672.
Response Final Office Action dated Feb. 11, 2016 in related U.S. Appl. No. 14/154,093.
Response Final Office Action dated Jan. 23, 2014 in related U.S. Appl. No. 13/108,698.
Response Final Office Action dated Mar. 14, 2017 in related U.S. Appl. No. 14/154,093.
Response Final Office Action dated Nov. 11, 2013 in related U.S. Appl. No. 13/108,698.
Response Final Office Action dated Oct. 28, 2014 in related U.S. Appl. No. 13/108,698.
Response Non Final Office Action dated May 1, 2014 in related U.S. Appl. No. 13/108,850.
Response Non-Compliant Amendment dated Sep. 23, 2016 in related U.S. Appl. No. 13/108,672.
Response Non-Final Office Action dated Apr. 20, 2015 in related U.S. Appl. No. 14/154,093.
Response NonFinal Office Action dated Aug. 28, 2008 in related U.S. Appl. No. 10/597,666.
Response Non-Final Office Action dated Jan. 6, 2017 in related U.S. Appl. No. 13/108,698.
Response Non-Final Office Action dated Jan. 6, 2017 in related U.S. Appl. No. 13/108,850.
Response Non-Final Office Action dated Jul. 9, 2015 in related U.S. Appl. No. 13/108,698.
Response Non-Final Office Action dated Jul. 9, 2015 in related U.S. Appl. No. 13/108,850.
Response Non-Final Office Action dated Jun. 10, 2016 in related U.S. Appl. No. 14/154,093.
Response NonFinal Office Action dated Jun. 13, 2012 in U.S. Appl. No. 13/308,698.
Response NonFinal Office Action dated May 1, 2014 in related U.S. Appl. No. 13/108,698.
Response Non-Final Office Action dated May 20, 2016 in related U.S. Appl. No. 13/108,672.
Response Non-Final Office Action dated Oct. 7, 2013 in related U.S. Appl. No. 13/108,672.
Response NonFinal Office Action dated Oct. 7, 2013 in related U.S. Appl. No. 13/108,850.
Response Non-Final Office Action dated Sep. 17, 2009 in U.S. Appl. No. 10/597,666.
Response Restriction Requirement dated May 20, 2013 in related U.S. Appl. No. 13/108,850.
Response Restriction Requirement dated Sep. 27, 2012 in related U.S. Appl. No. 13/108,698.
Response to Final Office Action dated Oct. 28, 2014 in related U.S. Appl. No. 13/108,850.
Response to Non -Final Office Action dated Feb. 19, 2019 in U.S. Appl. No. 15/668,622 (0406).
Response to Non-Final Office Action dated Oct. 23, 2020 in U.S. Appl. No. 16/878,228 (0408).
Response to Restriction Requirement dated Jul. 10, 2020 in U.S. Appl. No. 16/878,228 (0408).
Response to Restriction Requirement dated Jul. 19, 2021 in U.S. Appl. No. 16/672,420 (0407).
Response to Restriction Requirement dated Jul. 2, 2012 in related U.S. Appl. No. 13/108,672.
Restriction Requirement dated Jun. 29, 2021 in U.S. Appl. No. 16/672,420 (0407).
Restriction Requirement dated Jul. 9, 2020 in U.S. Appl. No. 16/878,228 (0408).
Restriction Requirement dated Feb. 20, 2013 in related U.S. Appl. No. 13/108,850.
Restriction Requirement dated Jun. 7, 2012 in U.S. Appl. No. 13/108,672.
Rich et al., “Atrial Septostomy as Palliative Therapy for Refractory Primary Pulmonary Hypertension,” Am J Cardiol., 51:1560-1561 (1983).
Ritzema et al., “Direct Left Atrial Pressure Monitoring in Ambulatory Heart Failure Patients—Initial Experience With a New Permanent Implantable Device,” Circulation, 116:2952-2959 (2007).
Ritzema et al., “Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure,” Circulation, 121:1086-1095 (2010).
Roberts et al., “Integrated microscopy techniques for comprehensive pathology evaluation of an implantable left atrial pressure sensor,” J Histotechnology, 36(1):17-24 (2013).
Rodes-Cabau et al., “Interatrial Shunting for Heart Failure Early and Late Results From the First-in-Human Experience With the V-Wave System,” J Am Coll Cardiol Intv., 11:2300-2310.doi :10.1016/j.cin.2018.07.001 (2018).
Rosenquist et al., Atrial Septal Thickness and Area in Normal Heart Specimens and in Those With Ostium Secundum Atrial Septal Defects, J. Clin. Ultrasound, 7:345-348 (1979).
Ross et al., “Interatrial Communication and Left Atrial Hypertension—A Cause of Continuous Murmur,” Circulation, 28:853-860 (1963).
Rossignol, et al., Left-to-Right Atrial Shunting: New Hope for Heart Failure, www.thelancet.com, 387:1253-1255 (2016).
Roven, Effect of Compromising Right Ventricular Function in Left Ventricular Failure by Means of Interatrial and Other Shunts 24:209-219 (Aug. 1969).
Salehian, et al., Improvements in Cardiac Form and Function After Transcatheter Closure of Secundum Atrial Septal Defects, Journal of the American College of Cardiology, 45(4):499-504 (2005).
Sandoval et al., “Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension,” Eur Respir J., 38:1343-1348 (2011).
Sandoval et al., “Graded Balloon Dilation Atrial Septostomy in Severe Primary Pulmonary Hypertension—A Therapeutic Alternative for Patients Nonresponsive to Vasodilator Treatment,” JACC, 32(2):297-304 (1998).
Schiff et al., “Decompensated heart failure: symptoms, patterns of onset, and contributing factors,” Am J. Med., 114(8):625-630 (2003) (Abstract Only).
Schmitto, et al., Chronic Heart Failure Induced by Multiple Sequential Coronary Microembolization in sheep, The International Journal of Artificial Organs, 31(4):348-353 (2008).
Schneider et al., “Fate of a Modified Fenestration of Atrial Septal Occluder Device after Transcatheter Closure of Atrial Septal Defects in Elderly Patients,” J Interven Cardiol., 24:485-490 (2011).
Scholl et al., “Surface Acoustic Wave Devices for Sensor Applications,” Phys Status Solidi Appl Res., 185(1):47-58 (2001) (Abstract Only).
Schubert, et al., Left ventricular Conditioning in the Elderly Patient to Prevent Congestive Heart Failure After Transcatheter Closure of the Atrial Septal Defect, Catheterization and Cardiovascular Interventions, 64(3): 333-337 (2005).
Second Preliminary Amendment dated May 8, 2018 in U.S. Appl. No. 15/668,622 (0406).
Setoguchi et al., “Repeated hospitalizations predict mortality in the community population with heart failure,” Am Heart J., 154:260-266 (2007).
Shah et al., “Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction—5-Year Outcomes,” J Am Coll Cardiol., https://doi.Org/10.1016/j.jacc.2017.08.074 (2017).
Shah et al., “One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF I) Trial—A Randomized Clinical Trial,” JAMA Cardiol. doi:10.1001/jamacardio.2018.2936 (2018).
Sitbon et al., “Selexipag for the Treatment of Pulmonary Arterial Hypertension.,” N Engl J Med., 373(26):2522-2533 (2015).
Sitbon et al., “Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience,” Eur Respir Rev., 26:160055:1-14 (2017).
Steimle et al., “Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors With Advanced Heart Failure,” Circulation, 96:1165-1172 (1997).
Stevenson et al., “The Limited Reliability of Physical Signs for Estimating Hemodynamics in Chronic Heart Failure,” JAMA, 261(6):884-888 (1989) (Abstract Only).
Stormer, et al., Comparative Study of in Vitro Flow Characteristics Between a Human Aortic Valve and a Designed Aortic Valve and Six Corresponding Types of Prosthetic Heart Valves, European Surgical Research 8(2):117-131 (1976).
Stumper, et al., Modified Technique of Stent Fenestration of the Atrial Septum, Heart, 89:1227-1230, (2003).
Su et al., “A film bulk acoustic resonator pressure sensor based on lateral field excitation,” International Journal of Distributed Sensor Networks, 14(11):1-8 (2018).
Supplementary European Search Report dated Nov. 13, 2009 in EP Patent Appl. Serial No. 05703174.2 (0430).
Thenappan et al., “Evolving Epidemiology of Pulmonary Arterial Hypertension,” Am J Resp Critical Care Med., 186:707-709 (2012).
Tomai et al., “Acute Left Ventricular Failure After Transcatheter Closure of a Secundum Atrial Septal Defect in a Patient With Coronary Artery Disease: A Critical Reappraisal,” Catheterization and Cardiovascular Interventions, 55:97-99 (2002).
Torbicki et al., “Atrial Septostomy,” The Right Heart, 305-316 (2014).
Trainor, et al., Comparative Pathology of an Implantable Left Atrial Pressure Sensor, ASAIO Journal, Clinical Cardiovascular/Cardiopulmonary Bypass, 59(5):486-492 (2013).
Troost et al., “A Modified Technique of Stent Fenestration of the Interatrial Septum Improves Patients With Pulmonary Hypertension,” Catheterization and Cardiovascular Interventions, 73:173179 (2009).
Troughton et al., “Direct Left Atrial Pressure Monitoring in Severe Heart Failure: Long-Term Sensor Performance,” J. of Cardiovasc. Trans. Res., 4:3-13 (2011).
U.S. Final Office Action dated Jan. 31, 2014 in related U.S. Appl. No. 13/108,672.
U.S. Non-Final Office Action dated Jan. 21, 2016 in related U.S. Appl. No. 13/108,672.
U.S. Notice of Allowance dated May 5, 2017 in related U.S. Appl. No. 13/108,672.
U.S. Notice of Allowance dated Oct. 6, 2011 in related U.S. Appl. No. 10/597,666.
U.S. Office Action dated Mar. 24, 2009 in related U.S. Appl. No. 10/597,666.
U.S. Supplemental Notice of Allowability dated Jun. 29, 2017 in related U.S. Appl. No. 13/108,672.
Vank-Noordegraaf et al., “Right Heart Adaptation to Pulmonary Arterial Hypertension—Physiology and Pathobiology,” J Am Coll Cardiol., 62(25):D22-33 (2013).
Verel et al., “Comparison of left atrial pressure and wedge pulmonary capillary pressure—Pressure gradients between left atrium and left ventricle,” British Heart J., 32:99-102 (1970).
Viaene et al., “Pulmonary oedema after percutaneous ASD-closure,” Acta Cardiol., 65(2):257-260 (2010).
Wang et al., “A Low Temperature Drifting Acoustic Wave Pressure Sensor with an Integrated Vacuum Cavity for Absolute Pressure Sensing,” Sensors, 20(1788):1-13 (2020).
Wang et al., “Tire Pressure Monitoring System and Wireless Passive Surface Acoustic Wave Sensor,” Appl Meeh Mater., 536(537):333-337 (2014).
Warnes et al., “ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease—A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease),” JACC, 52(23):e143-e263 (2008).
Webb et al., “Atrial Septal Defects in the Adult Recent Progress and Overview,” Circulation, 114:1645-1653 (2006).
Wiedemann, H.R., “Earliest description by Johann Friedrich Meckel, Senior (1750) of what is known today as Lutembacher syndrome (1916),” Am J Med Genet., 53(1):59-64 (1994) (Abstract Only).
Written Opinion of the International Searching Authority dated Apr. 7, 2008 in Int'l PCT Patent Appl. Serial No. PCT/IL05/00131 (0410).
Yantchev et al., “Thin Film Lamb Wave Resonators in Frequency Control and Sensing Applications: A Review,” Journal of Micromechanics and Microengineering, 23(4):043001 (2013).
Zhang et al., “Acute left ventricular failure after transcatheter closure of a secundum atrial septal defect in a patient with hypertrophic cardiomyopathy,” Chin Med J., 124(4):618-621 (2011).
Zhang et al., “Film bulk acoustic resonator-based high-performance pressure sensor integrated with temperature control system,” J Micromech Microeng., 27(4):1-10 (2017).
Zhou, et al., Unidirectional Valve Patch for Repair of Cardiac Septal Defects with Pulmonary Hypertension, Annals of Thoracic Surgeons, 60:1245-1249, (1995).
Related Publications (1)
Number Date Country
20220183838 A1 Jun 2022 US
Provisional Applications (2)
Number Date Country
60573378 May 2004 US
60541267 Feb 2004 US
Divisions (1)
Number Date Country
Parent 13108672 May 2011 US
Child 15668622 US
Continuations (3)
Number Date Country
Parent 16672420 Nov 2019 US
Child 17653551 US
Parent 15668622 Aug 2017 US
Child 16672420 US
Parent 10597666 US
Child 13108672 US